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1. INTRODUCTION 
Metal ions are essential for many metabolic pathways; their homeostasis 
is crucial for life and, remarkable, are involved in many important 
processes including respiration, nitrogen and carbon cycling, gene 
regulation, replication and repair of DNA, antioxidant defense, 
neurotransmission.1 Scarce bioavailability of some metal ions may 
determine diseases. Well known examples include pernicious anemia 
resulting from iron deficiency, growth retardation arising from insufficient 
dietary zinc, and heart disease in infants owing to copper deficiency. 
Metal ions can also induce toxicity in humans, classic examples being 
heavy-metal poisons such as mercury and lead. Even essential metal 
ions can be toxic when present in excess; iron is a common household 
poison worldwide as a result of accidental ingestion, usually by children, 
of the dietary supplement ferrous sulfate. Despite their important 
biological role is today commonly known, conversely, it is less known the 
role and the potential that metal ions have in medicine.2   
The medicinal properties of metals have been known and used since very 
ancient times. Silver’s association with anti-bacterial properties has long 
been established. Phoenicians knew enough to keep water, wine and 
vinegar in silver vessels to ensure freshness. The ancient Egyptians also 
knew how to sterilize water with copper.  
The field of inorganic chemistry in medicine may usefully be divided into 
two main categories: firstly, ligands as drugs which target metal ions in 
some form, whether free or protein-bound; and secondly, metal-based 
drugs and imaging agents where the central metal ion is usually the key 
feature of the mechanism of action.3 Our attention will be focused on this 
latter category. Research of new efficient metal-based drugs, has 
attracted growing attention  in the last decades for their potential 
applications in different fields of medicine and, the efforts carried out, 
have produced a series of metal-based drugs in widespread use, being 
today an important arsenal in therapy and diagnosis of many diseases. 
Significant examples of metal-based drugs currently in clinic are 
Auranofin (Ridaura™), introduced since 1985 for the treatment of 
progressive rheumatoid arthritis resistant to conventional therapy,4 silver 
sulfadiazine (FlamazineTM) used for prophylaxis and treatment of infection 
in burn wounds, arsenic trioxide (TrisenoxTM), effective against acute 
promyelocytic leukemia.3,5 A more detailed list of some inorganic 
compounds used for medical purposes is shown as table 1. 
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Element Compound Uses Trade names 
Li Li2CO3 Manic depression Camcolit, Lithane 
Fe [Fe(NO)(CN)5]2- Vasodilation Nipride 
Ga  Ga(NO3)3 Hypercalcemia Ganite 
As As2O3 Anticancer agent Trisenox 
Ag AgNO3 Ag (sulfadiazine) 
Disinfectant 
Antibacterial Flamazine, Silvadene 
Sb Sb3+ (tartrate) Antiparasitic, leishmaniasis Stibophen 
Pt Cis-[Pt(amine)2X2] Anticancer agents Platinol, Paraplatin, 
 Eloxatine 
Au Au(Pet3)(acetyl-thioglucose) Rheumatoid arthritis Ridaura 
Bi Bi(sugar)polymers Antiulcer, antacid Pepto-Bismol, Ranitidine Bismutrex, De-Nol 
Hg Hg-organic compounds Antibacterial Thiomersal, mercurochrome 
 
Table1 Medical uses of inorganic compounds (Table from ref. 3) 
 
In addition, gadolinium-based contrast agents are successfully used 
today to improve the quality of MRI and X ray images, so that it is 
possible to succeed in early stage diagnosis for different diseases; also, 
many patients, receive injections of a 99mTc compounds for 
radiodiagnostic purposes.2 
In any case, and despite the important role of 
these complexes in the modern medicine, the 
best known example of a small molecule metal-
containing drug, is cisplatin (cis-PtCl2(NH3)2,  
also known as cis-DDP). Cisplatin, originally 
known as Peyrone’s chloride, was first prepared 
in its presently used form by Italian chemist 
Michele Peyrone in 1844.6 It later played a 
central role in the Nobel prize-winning work of 
swiss chemist Alfred Werner (1866-1919) on 
isomerism in inorganic complexes. The cytostatic activity of cisplatin was 
first reported by Barnett Rosenberg (1926-2009) and co-workers in 
1965,7,8 and it progressed rapidly into the clinic until its approval by FDA 
in 1978 for the treatment of ovarian and testicular cancer.9 To date 
cisplatin (with its second generation analogues carboplatin and 
oxaliplatin) is used in almost 50% of clinical protocols for cancer 
treatment.10  
Despite its great curative success in testicular cancer, cisplatin is not 
universally effective against cancer and induces a number of important 
side effects. In fact, not all cancers are responsive to cisplatin therapy 
(intrinsic resistance), some other instead,  become resistant to cisplatin 
during the treatment, especially if prolonged (acquired resistance).  
Figure 1 Barnett Rosenberg 
and Loretta Van Camp April 
24, 1969. 
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To overcome these problems, new platinum complexes have been 
pursued and investigated for their antitumor properties. Although well 
over a thousand complexes have been prepared and tested thus far, only 
two other platinum drugs are approved for clinical use worldwide (i.e. 
carboplatin and oxaliplatin), and few additional compounds are approved 
for regional use in Asia. These complexes, operate with a mechanism of 
action similar to that of cisplatin, which involves DNA binding and 
transcription inhibition.11 Hence, there is the urgent need to develop new 
antineoplastic agents able to circumvent these drawbacks and active 
toward those forms of cancer resistant to conventional platinum-based 
drugs. This doctoral thesis, hopefully, will contribute to the research in the 
field of platinum antineoplastic agents, to reach the goal of new and more 
effective treatments. To this end, interaction of cisplatin, carboplatin and 
oxaliplatin with model proteins will be tested and mechanistic 
considerations will be made. Starting from the observation made for these 
drugs, new likely drug candidates will be studied comparatively, their 
antiproliferative effect determined and possible further development 
discussed.  
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1.1 Cisplatin and its analogues, Pt-drugs used in clinical protocols 
and new candidates 
Cisplatin (Figure 2, structure (1)) is a highly effective chemotherapeutic 
drug. Since its approval in 1978, its application has expanded to several 
types of cancer, administered either alone or in combination with other 
drugs/treatments. Currently, cisplatin is approved for the treatment of 
several cancers such as ovarian, testicular, cervical, non-small cell lung, 
head and neck, bladder and malignant mesothelioma.12-15 Although this 
success there are, as already mentioned, severe limitations to its use and 
effectiveness. Some cancer is resistant to cisplatin and in other cases 
resistance arise during treatment and there are dose-limiting side effects 
such as nephrotoxicity, neurotoxicity, emetogenesis, ototoxicity and bone 
marrow suppression during and after therapy. These aspects led to 
development of “second-generation” platinum-based drugs (Figure 2). 
 
Figure 2 Structures of platinum anticancer drugs in clinical use. 
Carboplatin ([Pt(cbdca-O,O’)(NH3)2]; where  cbdca is cyclobutane-1,1-
dicarboxylate and O and O’ are the ligand donor atoms) (Figure 2, 
structure (2)), was reported by Cleare and Hoeschele in 197316,17 and 
entered the clinic in 1998 (ParaplatinTM) principally in response to the 
necessity to reduce the toxic side effects of the parent drug. Despite its 
lower toxicity (especially oto and neprotoxicity), carboplatin is essentially 
active in the same set of tumors as cisplatin and a broader spectrum of 
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activity is not indicated.18 In addition, for some tumors, cisplatin appears 
to be therapeutically more effective than carboplatin (germ cell tumors, 
head and neck, and bladder) whereas for lung cancer and ovarian cancer 
effectiveness is comparable.3 
Since the advent of cisplatin in the clinic, the three main goals for drug 
development have been improvement of toxicity profile, circumvention of 
resistance, and expansion of the cancer cells sensitive to treatment by 
cisplatin. The importance of circumventing resistance was recognized 
very early on and reports of the activity of complexes containing 1,2-
diaminocyclohexane (dach) in murine L1210 resistant to cisplatin date 
back to 1978.3,19 Oxaliplatin ([Pt(ox-O,O’) ((1R,2R)-dach-N,N’)]), where ox 
is oxalate and dach is 1,2-diaminocyclohexane (Figure 2, structure (3)), is 
a platinum anticancer drug which gained approval for clinical use in the 
European Union in 1999 and in the United States in 2002.20-22  
Oxaliplatin is especially effective against colorectal cancer (CRC), where 
it is widely used in the adjuvant chemotherapy that mainly relies on 
fluoropyrimidine compounds combined with oxaliplatin. Indeed, either the 
FOLFOX (5-FU, leucovorin, and oxaliplatin) or CapeOx (capecitabine and 
oxaliplatin) regimens are used most often. Remarkably oxaliplatin is much 
less nephro- and ototoxic than cisplatin and can be used to treat cisplatin-
resistant tumors, also, it is less myelosuppresive than carboplatin. An 
important limitation of oxaliplatin is that the drug induces peripheral 
neuropathy (nerve damage), the result is sensation to cold which for 
acute (brief) exposure, occurs quickly after administration and is 
reversible.23 Since Ca2+ ions are important in the neuronal signaling 
system, this form of neuropathy may be caused by the complexation of 
the oxalate ligand released from the drug, with Ca+2. In chronic (continual) 
exposure to oxaliplatin, the drug-induced neuropathy is not totally 
reversible. This form of nerve damage is thought to be related to 
accumulation of the drug in the cells located in the dorsal root ganglion of 
the spinal system and the subsequent decrease in cellular metabolism.20 
Cisplatin, carboplatin and oxaliplatin are the only three Pt-drugs approved 
worldwide.  
Other cisplatin analogues have gained regional approval, some are to 
date, in clinical trials in different countries. 
Among these, Nedaplatin (cis-diammineglycolatoplatinum(II)) (Figure 2, 
structure (4)) is currently used in Japan to treat ovarian and cervix 
carcinomas, head and neck tumors, esophageal and bladder cancer.24 
Nedaplatin is in some ways similar to carboplatin in that it does not 
appear to use organic cation transporters for entering the cell and it is 
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myelosuppresive, which limits the dose that can be administered to the 
patient.25,26  
Lobaplatin (D-19466; 1,2-diammino-methyl-cyclobutaneplatinum(II)-
lactate) (Figure 2, structure (5))  has been approved in China for 
treatment of different cancers (e.g. the treatment of SCLC, chronic 
myelogenous leukaemia, and inoperable metastatic breast cancer).20,27 
Even lobaplatin exhibits few of the side effects of cisplatin.  
At variance, heptaplatin (Figure 2, structure (6)) has been approved in 
South Korea and often used in protocols for gastric cancer treatment and, 
in combination with paclitaxel, against head and neck squamous 
cancers.20 Also this compound presents important side effects such as 
mild hepatotoxicity and myelosuppression while its nephrotoxicity is dose-
limiting. Overall, the choice of the most appropriate analogue is a function 
of the cancer being treated, treatment intention (palliative or curative), 
and other component drugs used in combination.3 Beyond these 
complexes, that have received global or local approval for their use in 
clinic, other platinum complexes have been or still are in clinical trials. 
Among these, an interesting complex is satraplatin (Figure 3, structure 
(1)), a Pt(IV) entered in clinical trials in the United States for treatment of 
lung non-small cells cancer, resistant prostate cancer and other 
malignancies, with the very favourable feature of oral administration. To 
date was not approved due to its performances, very similar to those of 
established drugs.27    
 
 
 
Figure 3 Structures of platinum anticancer drugs in clinical trials. 
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Picoplatin (Figure 3, structure (2)) reached clinical phase III. This drug is  
active against cisplatin-resistant cell lines and cell lines that have 
enhanced mechanisms for removing platinum from the cell, complexing 
platinum to cellular thiols or removing platinum from DNA.28 Picoplatin 
appears to have good bioavailability when given orally, and this 
represents an interesting feature. The side effects of picoplatin include 
nausea, vomiting, anorexia and a transient metallic taste, but there is no 
or very little nephro- or neurotoxicity with the agent.20,29 
BBR3464 (Figure 3, structure (3)) is a trinuclear complex developed by 
Farrell and coworkers, that reached clinical phase II. In clinical trials in the 
United States, BBR3464 is showing activity against melanoma, and 
against metastatic pancreatic and lung cancers. The dose-limiting 
toxicities with BBR3464 are determine by bone depression, and 
diarrhea.20   
 
1.2 Chemistry and biology of conventional Pt-based antineoplastic 
agents: how these drugs work? 
 
Almost 40 years after its approval, studies on cisplatin and analogues, still 
continue in an effort to understand exactly how these drugs work.30 
It is commonly accepted that the primary target of cisplatin is DNA. After 
intravenous administration cisplatin enters in the bloodstream and once 
reached the cells is internalised. Cellular environment allows cisplatin 
activation due to the low concentration of Cl- ions (~ 4 mM against ~ 103 
mM of blood plasma).31 The resulting platinum(II) aqua complexes are 
potent electrophiles that readily react with a number of biological ligands 
with loss of the bound water molecules. The purine bases of nucleic acids 
are strongly nucleophilic at the N7 position. Thus, cisplatin binds readily 
to DNA, forming primarily bifunctional adducts with loss of both chloride 
ligands.11 
Overall the mechanism of cisplatin action (as well as for other clinical Pt-
based drugs) is a multi-step process that includes: (i) cisplatin 
accumulation, (ii) activation and (iii) cellular processing.32 
 
1.2.1 Accumulation 
 
The mechanism by which cisplatin and its analogues enter cells is still 
under debate.32,33 To date is not completely recognised whether cisplatin 
enters cells in an active or passive way, both mechanisms are most 
probably involved in platinum uptake process and play an important role 
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in the cell resistance mechanisms.34,35 It is likely that cisplatin reaches 
cells in its neutral form considering high chloride concentration in the 
extracellular environment. More recently, it was discovered that cisplatin 
might find its way into cells via active transport mediated by the plasma-
membrane copper transporter Ctr1p present in yeast and mammals.36 
Details about this active transport remain to be elucidated. Recent studies 
with Ctr1p-/- mouse embryonic fibroblasts exposed to 2 µM cisplatin or 
carboplatin revealed only 35% of platinum accumulation compared to that 
taken up by Ctr1p wild type cells, which supports such an active transport 
mechanism. Most likely there are multiple pathways by which the drug is 
internalized.32 Details for these process are summarised in figure 4. 
 
 
 
 
Figure 4 Cellular uptake of Cisplatin. Before internalization the drug may react with 
proteins (e.g. HSA). Internalisation occurs through active and/or passive transportation. 
Activation occurs due to the drop of [Cl-] inside the cells. Despite DNA is believed to be 
the main target for final pharmacological effect, even interactions with protein lead to 
cellular processes alteration/response. 
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1.2.2 Activation and binding to biological targets  
As already reported above, activation of cisplatin occurs when the drug is 
internalised in the cell. Here, the drop of chloride anion concentration 
triggers a series of reaction leading to the corresponding aquated cationic 
species of  cisplatin (Figure 5). These species are very reactive and able 
to bind biological targets such as DNA and proteins.37 
 
 
 
 
Figure 5 Activation of cisplatin in the cellular environment. 
After activation, Pt(II) aqua complexes are capable to react with a number 
of targets, through release of water molecules. Interaction with nuclear 
DNA is believed to contribute in a major way to the antitumor activity of 
cisplatin being the purine bases at the N7 position the primary target for 
the formation of cisplatin-DNA adducts. The major cisplatin−DNA adduct 
is the intrastrand 1,2-d(GpG) cross-link, which accounts for 60−65% of 
the bound platinum. Interactions, which distort and bend the DNA 
structure, impede transcription and the downstream effects of 
transcription inhibition ultimately lead to cell death.11,38 
Overall, formation of different adducts in different positions of double helix 
DNA is possible, as depicted in figure 6.38 
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Figure 6 Platinum binding site on DNA bases (A) and types of cisplatin-DNA adducts and 
their frequency (B) (arrow: possible platination site; dotted arrow: possible metal binding 
only after loss of H+).38 
Apart from DNA, cisplatin and its analogues are able to bind aminoacidic 
residues of proteins. Due to the high affinity of thiolate anions for 
platinum, the complex may bind sulfur atoms. Important examples of this 
mode of interaction is represented by coordination of metal center to 
glutathione and metallothionein.39 This latter aspect is of central 
importance since these proteins defend the cell against cisplatin itself,40 
and continuous exposure to the drug can build up resistance owing to 
increased levels of glutathione and metallothioneins.41     
In addition cisplatin may binds also to blood serum proteins with important 
consequences in terms of toxicity (i.e. by inhibition of crucial role of 
proteins) as well as in terms of bioavailability (i.e. drug inactivation or 
“drug reservoir”). Remarkable, between many protein, serum albumin 
(HSA) is the most abundant (average blood content of 40–45 g L-1 in 
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healthy humans) and one day after intravenous administration of cisplatin, 
65 to 98% of total Pt is bound to plasma proteins, in particular to HSA. 
Different opinions still exist on the consequences of cisplatin binding to 
HSA. Some authors report that HSA inactivates cisplatin and its 
analogues through coordination and binding of metal fragments, some 
others suggest that HSA is a reservoir of activated species of cisplatin still 
capable to transport and deliver these species to tissues.42 
These issues are not trivial to be solved, but nowadays appears clear that 
interaction with proteins of metal-based drugs, plays a key role in terms of 
final pharmacological effect and thus, it is of great interest its 
understanding and characterisation. 
1.2.3 Cellular processing, response to DNA damage  
The pharmacological effect of cisplatin is determined by its interaction 
(and adducts formation) with nuclear DNA.  Consequently  a series of 
different pathways are activated and these, finally lead to inhibition of 
DNA transcription and replication. The interstrand and intrastrand 
crosslinks disrupt the structure of the DNA and this alteration in the 
structure is recognized by the cellular proteins to repair cisplatin-induced 
DNA damage.31,32 
To date several families of proteins are considered to be important from 
this point of view: 1) nucleotide excision repair (NER) proteins, 2) 
mismatch repair (MMR) proteins, 3) DNA-dependent protein kinase 
(DNA-PK), and 4) high-mobility group (HMG) proteins. 
Since the intrastrand cross-link is the major lesion caused by cisplatin-
induced DNA damage, it is primarily repaired via the nucleotide excision 
repair (NER) system. The activity and efficacy of this process varies 
depending upon the nature of the adducts. NER in human cells depends 
on many factors, which include the XPA and RPA proteins, incision by 
structure-specific endonucleases, and repair DNA synthesis mediated by 
DNA polymerase.43,44 Characterisation of the different repair pathways is 
of central importance to design more efficient platinum complexes able to 
overcome the cancer resistance due to these mechanisms of damage 
recognition. In this frame one potentially important factor is specific 
binding of HMGB proteins to 1,2-intrastrand cisplatin–DNA crosslinks, 
which shield these lesions from recognition of NER.45-47 Furthermore, very 
important role is played by the p53 gene. When the DNA in a cell 
undergoes damage by cytotoxic agents (i.e. cisplatin or its analogues), 
radiation, p53 protein is extremely important in order to determine 
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whether the DNA will be repaired or the damaged cell will self-destruct 
(undergoes apoptosis). If the DNA can be repaired, p53 activates other 
genes to fix the damage. If the DNA cannot be repaired, this protein 
prevents the cell from dividing and signals it to undergo apoptosis.47,48  
 
 
Figure 7 Schematic representation of cell response to cisplatin-induced DNA damage.48  
Thus, there are many pathways involved in the response to DNA 
damage, that overall, determine the fate of the cell. Still, efforts of 
researchers are focused on a complete understanding of all these 
processes.    
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2. AIMS AND OBJECTIVES OF THE RESEARCH 
In the last decades the research on inorganic drugs in medicine has 
registered remarkable progresses with particular emphasis to the field of 
anticancer drugs.1 Cisplatin, carboplatin and oxaliplatin are today widely 
used in the treatment of different type of malignance and often represent, 
even in combination with other drugs, a first choice therapy.2 Since the 
serendipitous discover of cisplatin and despite the efforts, still nowadays,  
these drug are the most important research products in this field, although 
resistance to the treatments and heavy side effects, are important limiting 
factors to their use in clinical protocols.3-5 Thus, there is urgent need of 
new and more effective Pt-based anticancer drugs able to circumvent 
these problems. 
 
The development of new metal-based anticancer  molecules is not easy, 
mostly because it is difficult to predict their effects in vivo, starting from 
the analysis of the cellular effects in vitro. Furthermore it should taken into 
account the extreme complexity of biological systems; even limiting our 
consideration only to studies at the cellular level, already, there are an 
outstanding number of factors and variables to be consider.  
 
In this frame we have carried out studies on cell-free systems as well as 
cellular studies, characterising the reactivity and the cellular effects of 
cisplatin and a series of its analogues to shed light on analogies and 
differences between these drugs. Interestingly, it has been extensively 
characterised their interaction with model proteins. Despite today it is 
recognised that formation of Pt-protein adducts, is of central importance 
in relation to overall pharmacological and toxicological impact of cisplatin 
and its analogues, yet, the structural information concerning platination of 
protein, and the characterization of the resulting adducts, is limited.6-8 
 
Thus the studies summarising in this thesis aimed to:  
 
i) gather information on mechanistic aspects correlated with the mode of 
action of Pt-based anticancer compounds that, to date, remains in part 
unclear; 
 
Aims and objectives of the research 
 
 
22 
 
ii) compare, at different level, the behaviour of conventional platinum 
anticancer drugs with experimental complexes in order to find differences 
that may be significant in terms of pharmacological effect in vivo,    
 
iii) evaluate or re-evaluate comparatively the anticancer properties of 
selected cisplatin analogues.  
 
All these issues are addressed within this work, where the comparative 
characterization of protein binding for conventional platinum-based 
anticancer drugs is reported (chapter 3) as well as the reappraisal of old 
cisplatin analogues, overlooked so far as anticancer agents, studied in 
comparison with clinical used Pt compounds (chapter 4 and 5). 
Preliminary in vivo studies are also described (chapter 6).        
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3. PROTEIN METALATION BY CONVENTIONAL Pt-BASED  
ANTICANCER DRUGS 
 
 
 
The results presented in this chapter have been published in the following 
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3.1 Introduction 
In our body we have thousands of proteins involved in many processes 
that are essential for life. Within these processes, proteins have 
structural, catalytic and transport roles. When a metal is introduced in the 
body, (e.g. as metal-based drug) it may bind to the aminoacidic residues. 
If an amminoacid is crucial for the biological activity of protein, (e.g. 
aminoacidic residues in the catalytic site of enzymes), the protein itself 
may undergo a perturbation that leads to the partial or complete lack of 
ability to perform its task, which could be enough to kill the cell.1,2       
Cisplatin and its analogues as well as many other metal-based drugs,  
are known to behave as pro-drugs. This implies that these complexes 
exert their interaction with biological targets and their pharmacological 
effects, after undergoing an activation process. Often (as in the case of 
cisplatin) this activation involves displacement of one or more weak 
ligands (leaving groups) and their replacement with water molecules; is 
this species that may react with protein side chains.3 Furthermore, 
activation, may occur through a redox process.4,5  
Among the 20 common amino acids found in proteins, only seven, 
aspartic and glutamic acids, histidine, lysine, methionine, cysteine and 
tyrosine, have donor atoms in their side chains that, from the standpoint 
of coordination chemistry, are potential targets for metallo-drugs.2 
The reaction of activated metallodrugs with protein side chains leads to 
formation of metallodrug-protein complexes, or adducts, in which metallic 
fragments are coordinatively bound to proteins. These adducts usually 
manifest a quite good stability.6-8 Moreover if the bound metal fragment 
presents additional reactive site or, if the metalated protein is reacted with  
other biomolecules with higher affinity for the metal, a residual reactivity 
may be expected. This residual reactivity may represent an important 
aspect in order to assess whether the formed species will conserve some 
biological role/activity.7 
Furthermore, the difficulties in developing new anticancer complexes is 
due to the limited knowledge of mechanistic aspects that lead to their 
internalization in tumor tissue and/or inactivation. Since drugs as cisplatin 
and its analogues, are administered intravenously, a particular attention 
should be devoted to the interactions occurring between metal complexes 
and biomolecules such as serum proteins. In fact these proteins may 
have a transport function for metal-based antineoplastic agents and may 
“assist” the uptake process. Also, plasma proteins may concur in 
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inactivation pathways of metal-based anticancer drugs (see chapter 1, 
section 1.2) and in those processes that are determining for activity, 
toxicity, bioavailability and  for excretion of the drugs themselves.9-11 
In this sense human serum albumin (HSA) and human serum transferrin 
play an important role. The former, is the most abundant plasma protein 
(about 52%) with a 40-45 g L-1 content in healthy humans (ca. 0.6 mM; 
Mw 66-67 kDa). It is a 66 kDa single-chain protein consisting of three 
domains (called I, II, and III), each comprising two helical subdomains 
(named A and B).12-15 Terminal regions of sequentially close domains 
form the interface helices that link domains to each other. Remarkably, 
the modular structural organization of HSA provides a variety of ligand 
binding sites that were extensively explored.15,16 
At physiological pH, albumin adopts helical conformation (67% R-helix 
content), and its amino acid sequence contains 17 disulfide groups, one 
thiol group (cysteine-34), and one tryptophan residue (tryptophan-214) 
with the mutual binding potential toward many types of compounds. The 
binding sites are located in hydrophobic cavities in subdomains IIA and 
IIIA. These binding locations were determined crystallographically for 
several binding partners.12 The protein was proven to bind and transport a 
variety of compounds, for example, fatty acids, bilirubin, metal ions, 
steroid hormones, vitamins, and pharmaceuticals, including 
metallodrugs.17 Serum albumin performs a number of physiologically 
important functions-control of osmotic blood pressure, transport, 
metabolism, distribution of various compounds (including drugs), radical 
deactivation and delivery of amino acids after hydrolysis for the synthesis 
of other proteins.12,14 
Human serum transferrin has a molecular mass of about 80 kDa and is 
found in blood plasma at a concentration of about 2.5 g L-1 (35 μM).18 The 
members of the transferring group in general possess a high degree of 
sequence homology, for example, 60% for trans- and lactoferrin. They are 
single-chain glycoproteins containing ca. 700 amino acids (679 amino 
acids in the case of transferrin). The chief physiological function of serum  
transferrin is undoubtedly in iron transport within the circulatory system.  
Transferrin is capable of binding two iron ions in oxidation state +3 (Fe3+ 
is bound selectively over Fe2+). The iron(III) binding sites are located both 
in the N- and in the C-terminal lobe, and the two lobes are highly 
homologous (ca. 40%). Each lobe contains a distorted octahedral Fe3+-
binding site consisting of two tyrosines, one histidine, one asparagine, 
and a bidentate carbonate ion that acts as a synergistic anion in the 
binding process. 
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Diferric transferrin was found to associate with cells at 37°C more strongly 
than the monoferric or apotransferrin (in this order of affinity). Once 
transferrin of whichever type is bound to the receptor it is processed by 
the cells.19 Inside the endosomes, the diferric transferrin releases the iron 
ions due to a lower pH (about 5.5) and becomes finally recycled back to 
the cell surface.9 
 
3.1.1 Model Proteins 
 
A very important point in this research area, is represented by the 
accurate characterization (and modellisation) of the interactions taking 
place between representative metallodrugs and protein side-chains. To 
reach this goal it is reasonable to assume that, in spite of the intrinsic 
structural diversity of the various proteins, some common patterns may 
hold in metal protein interactions related to the specific nature of the 
metal center and of protein side-chains. To this scope, studies of simple 
model proteins have turned out to be valuable.9,20,21 For our research we 
have selected two of these model proteins i.e. hen egg white lysozyme 
(HEWL) and Ribonuclease A (RNase A). These, are small size proteins 
(MW respectively 14300 and 13680 Da), are well known and 
characterised, commercially available and have been often used to 
characterise the interactions occurring between proteins and 
metallodrugs.20-22 
HEWL (Figure 1A) is a protein that has potent bactericidal properties, 
primarily ascribed to its enzymic activity, resulting in hydrolysis of b-
linkage between the N-acetylglucosamine and N-acetylmuramic acid of 
the bacterial peptidoglycan, causing cell lysis. Beyond its biological 
importance, HEWL is one of the most studied and best characterized 
globular proteins. It was the first enzyme to have its structure determined 
by X-ray diffraction,23 and since then hen lysozyme has been used 
extensively as a system to understand the underlying principles of 
proteins structure, function, dynamics, and folding through studies of both 
an experimental and theoretical nature.24 
Owing to its small size and to the prevalence of positively charged 
groups, is a particularly suitable protein for ESI-MS investigations as 
previously shown. In addition HEWL is very prone to crystallise, thus 
turning out very appropriate for X-ray diffraction characterisations of its 
metallodrug adducts.5,20,21 Potential binding sites for interaction with 
complexes are the histidine (e.g. His15) and methionine (e.g Met105 and 
Protein metalation by conventional Pt-based anticancer drugs 
 
 
31 
 
12) as well as aspartate residues. The 8 cysteine are instead involved in 
four disulphide bonds.    
                                                            
A B  
 
Figure 1 3D structure of HEWL solved at 1.33 Å. RCSB PBD 193L (A) and RNase solved 
at 1.26 Å RCSB PDB 7RSA (B). 
  
At variance, RNase (Figure 1B) was the first enzyme and third protein 
(after insulin and haemoglobin) for which a correct amino acid sequence 
was determined,25,26 and the third enzyme and fourth protein (after 
myoglobin, lysozyme, and carboxypeptidase A) whose three-dimensional 
structure was determined by X-ray diffraction analysis.27 
It is an endoribonuclease with the important role in catalysing the 
cleavage of the phosphodiester bond between the 5’-ribose of a 
nucleotide and the phosphate group attached to the 3’-ribose of an 
adjacent pyrimidine nucleotide. This cleavage forms a 2’,3’-cyclic 
phosphate, which is then hydrolysed to the corresponding 3’-nucleoside 
phosphate. 
RNase A contains four disulfide bonds, which are critical to the stability of 
the native enzyme. Two of these disulfide bonds lie between an alpha-
helix and a beta-sheet and contribute more to the thermal stability than do 
the other two. Likely binding sites for interaction with complexes are 
histidine, methionine and aspartate residues of protein side chains. Since 
its structure makes it very stable protein and, as in the case of HEWL, 
well suitable for ESI-MS experiments as well as for crystallography; 
RNase A has been the object of landmark work on the folding, stability, 
and chemistry of proteins; in enzymology and in molecular evolution 
beyond the metal-protein interaction studies.28  
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Overall, studies on metallodrugs and model proteins permit a precise 
characterisation of their interactions at molecular level. Of course,  it is 
mandatory to remember that we are studying very simplified systems. 
Indeed, in most cases the various biophysical studies have been mainly 
conducted on a two component systems containing a single metallodrug 
and a single protein. Nevertheless, despite these approximations, very 
interesting and useful informations may be derived from these studies, 
allowing to formulate mechanistic hypothesis. In addition comparing the 
different behaviour of complexes under the same conditions, it is possible 
to highlight those small differences that may have important 
consequences in vivo. 
 
3.1.2  Molecular mechanisms of protein platination, comparative 
studies of the adducts formed in the reaction of HEWL with 
oxaliplatin, cisplatin and carboplatin.  
 
3.1.2.1 Introduction 
 
Cisplatin, carboplatin and oxaliplatin (Figure 2) are the three most 
important platinum-based anticancer drugs in widespread clinical use for 
the medical treatment of various kinds of cancers.29 The mechanism of 
action of these compounds is believed to rely mostly on tight platinum(II) 
binding to DNA and consequent DNA damage.30 If not recognised and 
repaired, such DNA damage ultimately triggers apoptotic death of cancer 
cells. 
 
 
 
Figure 2 Structure of Cisplatin (1), Carboplatin (2)  and Oxaliplatin (3). 
 
In spite of the strict similarities in chemical structures and in DNA binding 
properties, these three Pt compounds manifest significant differences in 
their respective pharmacological profiles resulting in different therapeutic 
uses and indications.31 In particular, the pharmacological profile of 
oxaliplatin turns out to be markedly distinct from those of cisplatin and 
Protein metalation by conventional Pt-based anticancer drugs 
 
 
33 
 
carboplatin: owing to its peculiar biological behaviour, oxaliplatin has 
become the election drug for the treatment of colorectal cancer, a very 
common type of cancer scarcely responsive to cisplatin and carboplatin.32 
Recent investigations pointed out that, in order to better understand the 
complete pharmacological profiles of Pt-based drugs, their interactions 
with proteins and consequent adduct formation must be understood in 
greater detail.1,33 Platinum drugs are known to behave as prodrugs or 
“functional metal based drugs” according to Enzo Alessio’s 
categorisation:3 upon activation and release of a labile ligand, they are 
able to bind coordinatively to protein side chains. Extensive 
documentation of protein platination by established Pt drugs has been 
gathered during the last 15 years with the help of various biophysical 
methods.34-39 ESI-MS measurements on small model proteins allowed a 
direct insight into details of the protein metalation process.35 Conversely, 
a number of crystal structures of platinated proteins have been solved. In 
particular, the cisplatin adducts of hen egg white lysozyme,36 bovine 
pancreatic ribonuclease,37 bovine erythrocyte Cu, Zn superoxide 
dismutase38 and copper chaperone Atox-139 were structurally 
characterised. In the case of carboplatin, only the crystal structure of its 
lysozyme adduct has been determined.36 These studies showed that 
platination occurs through coordinative binding of Pt containing fragments 
to a few protein side chains such as histidines, cysteines or methionines. 
Also, we realised that no crystal structure was reported for protein 
adducts of oxaliplatin. 
These arguments prompted us to investigate the interactions of oxaliplatin 
with the model enzyme hen egg white lysozyme (HEWL) from the 
structural point of view. We chose HEWL for this study since its structure 
has been often used to characterise the interactions occurring between 
proteins and metallodrugs22,40; in addition, crystal structures of its 
complexes with both cisplatin and carboplatin are available.36  
 
3.1.2.2 Results 
 
Crystals of HEWL in the presence of oxaliplatin (protein to metal drug 
ratio 1:10, incubation time=24 h) have been grown by hanging drop 
vapour diffusion method using a reservoir solution of 0.6 M NaNO3, 0.1 M 
sodium acetate pH 4.4 and 20 % ethylene glycol. X-ray diffraction data 
have been collected on these crystals at 1.73 Å resolution using a 
Saturn944 CCD detector equipped with CuKα X-ray radiation from a 
Rigaku Micromax 007 HF generator (see experimental section for details) 
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and the crystal structure determined. This represents the first 
crystallographic study at high resolution for a protein adduct of oxaliplatin. 
The overall structure of the oxaliplatin-HEWL complex is shown in figure 
3. The structure has been refined to a R-factor of 0.180 (R-free=0.235). 
The general conformation of the protein is not significantly affected by 
oxaliplatin binding. Inspection of the difference Fourier electron-density 
map (Fo-Fc) clearly revealed one >15σ peak close to Asp119 (Figure 4). 
This peak has been easily attributed to the platinum ion. The coordination 
geometry around the metal center is almost planar. Pt(II) is covalently 
attached to Asp119 OD2 atom, to a water molecule and to the two N 
atoms of the cyclohexyldiamine ligand. 
 
 
 
Figure 3  Overall structure of HEWL-oxaliplatin. Coordinates and structure factors were 
deposited in the Protein Data Bank (PDB code 4PPO). 
 
 
                                  
Figure 4  Details of the binding site of oxaliplatin to HEWL. The Pt ion is coordinated to 
Asp119. The binding of oxaliplatin to HEWL is accompanied by the loss of the oxalate ion. 
2Fo-Fc electron density maps are contoured at 5σ (red) and 1σ (grey) level. 
 
Structural refinements suggested an occupancy value for the Pt atom 
around 0.7, this representing a quite relevant degree of protein 
metalation. The cyclohexyldiamine ligand well fits into a cavity formed by 
the side chains of residues Trp62, Trp63, Asp101 and Asn103 of a 
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symmetry-related molecule (Figure 5). This interchain complementarity 
allows a clear definition of this region. 
 
 
Figure 5 Stick representation of Pt binding site. Pt is bound to Asp119 side chain (cyan). 
The cyclohexyldiamine ligand is inserted into a cavity formed by Trp62, Trp63, Asp101 
and Asn103 residues of a symmetry related molecule (yellow). 
It is very instructive to compare the newly determined oxaliplatin-HEWL 
structure with those previously obtained for the HEWL adducts of cisplatin 
and carboplatin.36 Structures of the three adducts are synoptically 
represented in figure 6. 
A B C  
Figure 6 Overall structures of HEWL-cisplatin (green), HEWL-carboplatin (yellow) and 
HEWL-oxaliplatin (cyan). The metallodrug moieties bound to the protein are shown as 
spheres. 
Comparative analysis offers several clues on the reaction between Pt 
drugs and the model protein lysozyme and on the associated protein 
metalation processes. In particular, the following features clearly emerge 
from inspection of these structures: 
 
i) cisplatin and carboplatin behave very similarly, as they both produce a 
metalated lysozyme adduct where a [Pt(NH3)2]2+ fragment is invariantly 
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coordinated to solvent accessible His15; there is just some variability in 
the anchoring mode of the platinum fragment to His15. No other Pt 
binding sites are detected. 
ii) Oxaliplatin modifies lysozyme through protein coordination of a 
[Ptdach]2+ fragment; a monometalated protein derivative is formed. At 
variance with cisplatin and carboplatin, coordination of the [Ptdach]2+ 
cation selectively occurs at the level of the free carboxylate group of 
Asp119. Again, no secondary Pt binding sites are detected. 
To gain independent information on the oxaliplatin/HEWL system the 
reaction was investigated through ESI-MS according to previously 
established experimental procedures.36a The resulting ESI-MS spectra, 
collected after increasing time intervals, are shown in figure 7 (see 
experimental part for full spectrum).  
 
Figure 7 Close up of deconvoluted ESI-MS of  HEWL treated with 3*10-4 mol L-1 
oxaliplatin (metal:protein ratio = 3:1 in 20 mmol L-1 ammonium acetate  buffer, pH 6.8) 
recorded after 24 h (A), 48 h (B), 72 h (C) of incubation at 37°C. 
Notably, the ESI-MS spectrum, recorded after 24 hours, manifests a peak 
at 14701.86 Da, which matches the mass of a non-covalent adduct 
between oxaliplatin and HEWL in accordance with previous 
observations;36a-41 alternatively, this peak might be assigned to a covalent 
oxaliplatin-HEWL adduct with monodentate oxalate coordination to Pt(II). 
Remarkably, for longer incubation times, two new peaks centred at 
14611.86 and 14648.81 Da show up, which correspond respectively to a 
HEWL-[Ptdach]2+ and the same adduct plus K+ ion (see also experimental 
section for experimental and calculated isotope pattern). These results 
suggest that oxaliplatin could first interact non-covalently with HEWL, 
then the oxalate ligand is progressively released and the [Ptdach]2+ 
fragment coordinates to the protein. In a final ESI-MS experiment, HEWL 
Protein metalation by conventional Pt-based anticancer drugs 
 
 
37 
 
was simultaneously challenged with oxaliplatin and cisplatin. Evidence 
was gained for the formation of a bis-platinum adduct, though in very 
small amounts, supporting the view that the two platinum binding sites are 
independent (see paragraph 3.1.3). Thus, ESI-MS data are roughly 
consistent with the picture arising from crystallographic studies, though 
the applied experimental conditions in the two kinds of experiments are 
obviously  different.  
 
3.1.2.3 Discussion and conclusions 
 
On the ground of the structural and solution results reported here for the 
reaction of oxaliplatin with HEWL, some general trends in the reaction of 
Pt drugs with proteins may be delineated as summarised below.  
With the three major Pt complexes in clinical use, monometalated 
derivatives of lysozyme are mainly formed. Before protein binding, Pt 
complex activation is required consisting in the release of one or more 
labile ligands: two chlorides in the case of cisplatin, the 
cyclobutandicarboxylate ligand in the case of carboplatin; oxalate in the 
case of oxaliplatin. The activation process may manifest a large kinetic 
variability depending on the nature of the leaving group and on the 
possible “assistance” offered by the protein. Notably, the activation 
process could be preceded by non-covalent binding of the intact Pt drug 
to the protein; then, coordinative binding to the protein of the Pt 
containing fragment occurs: [Ptdach]2+ coordinates Asp119 while 
[Pt(NH3)2]2+ fragments are selective for His15. 
These results well reflect the fact that cisplatin and carboplatin manifest 
strictly related pharmacological profiles while oxaliplatin shows a rather 
distinct behaviour. It is possible that differences in reactivity and adduct 
formation with the model protein HEWL, as those above underscored, 
may have a more general meaning with respect to Pt drugs/protein 
interactions, and may account, at least in part, for the conspicuous 
differences in the respective pharmacological and toxicological profiles. 
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3.1.2.4 Experimental section 
Crystallization, Data collection and refinement 
Oxaliplatin and hen egg white lysozyme were obtained from Sigma. 
Crystals of HEWL in the presence of oxaliplatin were grown by hanging-
drop vapor diffusion technique at 298 K mixing a protein solution 
containing 15 mg mL-1 of  HEWL incubated for 24 h with an excess of 
oxaliplatin (protein to metal drug ration 1:10) with equal volumes of 
reservoir solution. Best crystals grow within 2-4 days from the following 
conditions: 0.6 M NaNO3, 0.1 M sodium acetate pH 4.4 and 20 % 
ethylene glycol. X-ray diffraction data were collected from a single crystal 
at the CNR Institute of Biostructure and Bioimages, Naples, Italy, using a 
Saturn944 CCD detector equipped with CuKα X-ray radiation from a 
Rigaku Micromax 007 HF generator. Crystals were slowly dehydrated at 
air42 and flash-frozen at 100 K using nitrogen gas produced by an Oxford 
Cryosystem (and maintained at 100 K during the data collection) without 
using cryoprotectants,43 following the procedure used in other works.44 
Data set was processed and scaled using the HKL2000 package.45 Data 
collection statistics are reported in table 1. 
The structure was solved by molecular replacement method, using the 
PDB file 4J1A,22 without water molecules and ligands, as starting model. 
The refinement was carried out with Refmac5.7,46 model building and 
map inspections were performed using Coot.47 5% of the data was used 
for calculation of the R-free value. After several rounds of refinement 
using the maximum likelihood option in Refmac, manual adjustments of 
side-chain atoms and addition of water molecules to the coordinates, the 
structure converged to Rfactor of 0.180 and to Rfree of 0.235. Refinement 
statistics are reported in table 1. Structure validation has been carried out 
using Procheck.48 Coordinates and structure factors were deposited in the 
Protein Data Bank (PDB code 4PPO).  
Distances between Pt and the other ligands are reported in table 2. 
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PDB code 4PPO 
Data-collection Space group 
 
P43212 
 
Unit cell parameters a=b,c (Å) 
 
77.05,37.29 
Molecules per asymmetric unit 1 
Observed reflections 44549 
Unique reflections 12001 
Resolution (Å) 50-1.73 (1.76-1.73) 
Completeness (%) 97.8 (96.8) 
Rmerge 0.088 (0.393) 
I/σ(I) 11.8 (2.8) 
Multiplicity 3.7 (2.3) 
Refinement 
Resolution (Å) 
30.8-1.73 
 
number of reflections in working set 11406 
number of reflections in test set 570 
R factor/Rfree (%) 0.180 (0.235) 
Number of non-H atoms used in the refinement 1163 
Occupancy of Pt ion 0.70 
B-factor of Pt ion 48.3 
Ramachandran values (%) 
Most favoured/ Additional allowed 
88.5/11.5 
Generously allowed/ Disallowed 0/0 
 
R.m.s.d. bonds (Å) 0.019 
R.m.s.d. angles(Å) 1.85 
 
 
Table 1 Data collection and refinement statistics for the oxaliplatin-HEWL structure. 
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   In the adduct In the CSD 
structure49  
In the structure of the  
adduct with 1,2-
D(GpG)50 
    
PDB code 4PPO CUHKEV 1IHH 
Pt-OD1 Asp119 2.05 - - 
Pt-O 1.98 2.01-2.03 - 
Pt-N 1.98-2.10
  
2.04-2.06 2.03-2.04 
Pt-N (DNA) - - 1.94-1.98 
N-Pt-O angle (°) 94.2 98.4-95.4 - 
O-Pt-O angle (°) 94.5 82.5 - 
N-Pt-N angle (°) 86.0 83.9 84.0 
N-Pt-N(DNA)  angle (°) - - 79.6-97.7 
N (DNA)-Pt-N(DNA)  
angle (°) 
- - 98.4 
 
 
Table 2 Selected bond lengths (Å) and angles (°) for the Oxaliplatin binding site in the 
adduct formed with HEWL, in the crystal structure of the Oxaliplatin (CSD code 
CUHKEV)49 and in the structure of the adduct with 1,2-d(GpG) (PDB code 1IHH).50 
 
 
ESI-MS experiments  
 
A solution of oxaliplatin (3*10-4 mol L-1)
 
with HEWL (3:1 complex/protein 
molar ratio) was incubated in ammomium acetate buffer solution 20 mM 
pH=6.8 at 37°C for 72 h and ESI-MS spectra were recorded after 6, 24, 
48, 72 h (Figure 8). After a 20-fold dilution with water, ESI-MS spectra 
were recorded by direct introduction at 5 μL min-1 flow rate in an Orbitrap 
high-resolution mass spectrometer (Thermo, San Jose, CA, USA), 
equipped with a conventional ESI source. The working conditions were 
the following: spray voltage 3.1 kV, capillary voltage 45 V, capillary 
temperature 220°C, tube lens voltage 230 V. The sheath and the auxiliary 
gases were set, respectively, at 17 (arbitrary units) and 1 (arbitrary units). 
For acquisition, Xcalibur 2.0. software (Thermo) was used and 
monoisotopic and average deconvoluted masses were obtained by using 
the integrated Xtract tool. For spectrum acquisition a nominal resolution 
(at m/z 400) of 100,000 was used. 
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Figure 8 Deconvoluted ESI-MS of  HEWL treated with 3*10-4 mol L-1 oxaliplatin 
(metal:protein ratio = 3:1 in 20 mmol L-1 ammonium acetate  buffer, pH 6.8) recorded after 
24 h (A), 48 h (B), 72 h (C) of incubation at 37°C. 
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Figure 9 Experimental and simulated  peak corresponding to [Pt(dach)]2+/lysozyme 
adduct. 
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3.1.3  Oxaliplatin vs Cisplatin: competition experiments  
in the binding to lysozyme 
 
3.1.3.1 Introduction 
In the previous section (3.1.2), we have shown that HEWL is able to bind 
cisplatin and oxaliplatin in two distinct binding sites,51 whereas cisplatin 
and carboplatin compete for the same residue side chain.52 In particular, 
upon reaction between cisplatin and HEWL, platination occurs at the level 
of His15, with a cis-Pt(NH3)22+ fragment bound to the protein surface.36,52 
On the other hand, the reaction between HEWL and oxaliplatin leads to 
the formation of a complex with Pt(dach)2+ moiety bound to Asp119.51 
These data suggest that, at least in principle, it is possible for these two 
Pt-drugs to bind HEWL simultaneously, although it is unpredictable if the 
binding of the former drug can alter the affinity of the protein for the latter. 
In fact, even subtle structural alterations can affect the HEWL dynamics, 
as already demonstrate in other works,55 thus altering the drug affinity for 
the protein. 
These arguments prompted us to investigate the formation of the adducts 
that are obtained when oxaliplatin and cisplatin are incubated with HEWL. 
These results are of potential interest if one considers that cisplatin and 
oxaliplatin might be clinically used in combination and that studies of 
cisplatin/oxaliplatin combination on patients with advanced ovarian cancer 
already revealed acceptable hematologic toxicity, and reversible 
cumulative neurosensory toxicity.56-58 Simultaneous injection of cisplatin 
and oxaliplatin was reported to produce a synergistic antitumor activity 
against cisplatin-resistant murine leukemia L1210.59,60 In addition, the 
feasibility and efficacy of a cisplatin/oxaliplatin combination was evaluated 
in patients with testicular tumors and encouraging results were  
obtained.61  
Along this line of reasoning, it should be also recalled that phase I clinical 
studies of a carboplatin/oxaliplatin combination revealed that the 
combination treatment seems feasible and active, although it does not 
allow a significant increase in platinum dose-intensity delivery.62 
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3.1.3.2 Results 
Electrospray mass spectrometry 
First, we registered ESI-MS spectra of HEWL sample in the presence of a 
mixture of equimolar concentrations of cisplatin and oxaliplatin (Figure 
10). A number of HEWL-platinum adducts are clearly visible in this 
experiment whose assignment is reported in table 3.  
 
Figure 10 ESI-MS spectrum registered to investigate the possible competition between 
oxaliplatin and cisplatin for the same binding site. The spectrum has been collected after 
24 h incubation of equimolar concentration of the two drugs (cisplatin and oxaliplatin) with 
HEWL in 20 mM ammonium acetate buffer pH=6.8 at 37°C (see experimental section for 
further details). For the peak assignment see table 3. 
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Label  Bound fragment         Mass (Da) 
a   Pt+Na+        14517.76 
b   [Pt(NH3)2]2+       14530.77 
c   [Pt(NH3)Cl]+       14550.50 
d   [Pt(NH3)2Cl]+       14567.76 
e   [Pt(NH3)2Cl]+ + Na+      14590.80 
f   [Pt(dach)]2+       14610.82 
g   [Pt(NH3)2Cl2] + Na+      14627.78 
h   [Pt(NH3)2Cl2] + 2Na+      14648.82 
i   Oxaliplatin       14701.84 
l   Oxaliplatin + [Pt(NH3)]2+     14915.82 
j                   2 Oxaliplatin       15098.89 
 
Table 3 Assignment of peaks in the ESI-MS spectrum (Figure 10). 
 
Interestingly, a protein-metallodrug complex is detected corresponding to 
a bis-Pt adduct (bis-adduct) with lysozyme simultaneously bearing an 
Pt(NH3)2+ fragment and an oxaliplatin molecule (peak l). The observation 
of this bis-adduct, though in a quite small amount, implies that the two 
drug binding sites on HEWL surface are independent one another. 
 
Crystallography 
Afterward, we tried to grow crystals of the bis-adduct following different 
strategies (see experimental section for further details). Attempts to 
obtain crystals of the bis-adduct mixing the protein to a mixture of 
cisplatin+oxaliplatin or adding first cisplatin and then oxaliplatin to the 
protein sample failed. In these cases we obtain crystals of the adduct 
between HEWL and cisplatin alone, i.e. structures of HEWL with Pt centre 
only bound to His15. On the other hand, tetragonal crystals of the bis-
adduct were successfully grown using a protein sample that was first 
incubated for 24 h with an excess of oxaliplatin and then incubated for 24 
h with an excess of cisplatin (final protein to metal ratio 1:10) and a 
reservoir solution containing 0.6 M NaNO3, 0.1 M sodium acetate pH 4.4 
and 20 % ethylene glycol. In the same experimental conditions, we also 
grew tetragonal crystals of a protein solution obtained when a HEWL 
sample with excess of cisplatin (1:10 protein to metal ratio) is mixed with 
equal amounts of protein with excess of oxaliplatin (1:10 protein to metal 
ratio). The results of the structural analyses carried out on crystals grown 
using these last two strategies show that the bis-adduct is formed (Figure 
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11). The structures were refined to R-factor of 0.155 and 0.159 and R-
free of 0.218 and 0.230 for the datasets collecting using the former and 
the latter procedure, respectively. The results obtained using the two 
datasets are almost identical, for this reason only one structure will be 
described. Both structures were deposited in the Protein Data Bank 
(accession code 4Z46 and 4ZEE). The overall structure of HEWL in the 
bis-adduct is not significantly affected by the binding of the two drugs.  
 
Figure 11 Overall structure of the bis-Pt HEWL adduct. Coordinates and structure factors 
were deposited in the Protein Data Bank (PDB code 4Z46). 
 
The CA root mean square deviation (rmsd) from the structure of ligand-
free HEWL (PDB code 193L) is as low as 0.26 Å. When the structure of 
the bis-adduct is compared with that of HEWL solved at ultrahigh 
resolution (PDB code 2VB1) and crystallized under similar experimental 
conditions, but in the triclinic space group, rmsd is in the range 0.79-0.81 
Å. The most significant differences between the atomic resolution 
structure of HEWL and the bis-adduct (Figure S1 in the supplementary 
material) are located in loop regions, close to residues 44-51 and 69-73 
(Figure S2A in the supplementary material), at the end of helix constituted 
by residues 88-101 and in the region connecting this helix to that 
encompassing residues 108-115 (Figure S2B in the supplementary 
material). These structural differences seem to be due to an altered 
disposition of nitrate ions on the molecular surface rather than to the 
binding of the drugs (Figure S2A and B).  
The inspection of the electron density maps of both bis-adduct structures 
suggest that there are two Pt binding sites on HEWL surface (Figure 12A 
and B and figures S3 and S4 in the supplementary material). As expected 
on the basis of the comparison between the structure of HEWL-cisplatin52 
and that of HEWL-oxaliplatin,51 the former binding site, i.e. presumably 
that of an oxaliplatin moiety, is close to Asp119 (Figure 12A). The latter, 
i.e. that presumably due to the binding of a cisplatin moiety, is found close 
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to His15 (Figure 12B). No other bindings sites are found, although 
multiple sites of cisplatin on HEWL had been found by ESI-MS combined 
with trypsin digestion.63 
 
A               B  
 
Figure 12 Binding sites of Oxaliplatin (A) and Cisplatin (B).2Fo-Fc electron density maps 
are contoured at 3σ (red) and 1σ (grey) level. 
In both the Pt binding sites observed in the bis-adduct, the Pt center has 
a low occupancy (Pt occupancy factor=0.40, B-factor=52.5-55.8 Å2 for the 
Asp119 binding site and Pt occupancy factor=0.35, B-factor=63.6-67.0 Å2 
for the His15 binding site, respectively). The location of the Pt centres is 
confirmed by the inspection of anomalous difference maps, which clearly 
identify the positions of the Pt atoms and of sulphur atoms of Cys6, 
Met12, Cys30, Cys64, Cys76, Cys80, Cys94, Met105, Cys115, Cys127 
(Figure 13 and Figure S5 in the supplementary material). 
 
Figure 13 Anomalous difference map calculated from anomalous data collected for the 
bis-adduct crystal. The anomalous map is rendered in blue and contoured at 2.0 σ. The 
map clearly identifies the positions of Pt and sulphur atoms of Cys6, Met12, Cys30, 
Cys64, Cys76, Cys80, Cys94, Met105, Cys115, Cys127. 
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Due to the low occupancies, details on the Pt coordination sphere cannot 
be easily resolved. However, a Pt(dach)2+ fragment close to Asp119 and 
a [Pt(NH3)Cl]+ fragment close to His15 have been identified and included 
in the final model. An independent confirmation of these assignments 
derives from the finding that the electron density maps of the Pt binding 
sites are almost identical in the two structures of the bis-adduct obtained 
using the two different preparations (Figure S3 and S4 in in the 
supplementary material). In the previous crystallographic study on the 
HEWL/carboplatin+cisplatin structures, both Pt drugs bind to His15, but 
cisplatin seems to have an overall higher binding affinity for the His15 
side-chain compared with carboplatin.64 
However, our structures cannot be directly compared with that obtained 
for HEWL/carboplatin+cisplatin,64 since the bis-adduct has not been 
obtained using the same procedure by Helliwell and Tanley. 
Surface plasmon resonance and circular dichroism analyses 
To further investigate the nature of HEWL/cisplatin+oxaliplatin interaction, 
surface plasmon resonance (SPR) and circular dichroism studies were 
also performed. First, the affinities of cisplatin and oxaliplatin toward 
HEWL were measured separately by SPR. This technique has been 
already used to evaluate the affinity of Pt complexes for G-
quadruplexes.65 HEWL was efficiently immobilized on a CM5-chip and Pt 
complexes were employed as analytes (concentration range 0.1-2.0 mM). 
Dose-response sensorgrams (Figure S6A and B in the supplementary 
material) revealed that, in 20 mM sodium citrate buffer at pH 4.4, the two 
molecules bind HEWL with similar affinities, in the low millimolar range 
(KD =1.83 ± 0.03 mM and 1.51 ± 0.02  mM, for cisplatin and oxaliplatin, 
respectively). Kinetic and thermodynamic parameters obtained by the 
SPR analysis are reported in table 4. For comparative purposes, the 
same experiments were then carried out in HBS (HEPES buffered saline) 
at pH 7.4 (Figure S6C). Cisplatin binding assays provided a similar value 
of KD (1.69 ± 0.05 mM), while oxaliplatin binding could not be evaluated 
due to the instability of the complex in the presence of NaCl.66 In fact, 
EXAFS spectra of oxaliplatin in NaCl solution concentrated between 0.08 
M and 3 M show that a slight enlargement of the band appears after a few 
hours, indicating that Pt chloration occurs.65  
Then, an experiment performed by injecting first oxaliplatin and then 
cisplatin (after reaching the saturation curve associated with the binding 
of the first ligand) was carried out (Figure 14). 
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Figure 14 SPR Sensorgram for the sequential injection of oxaliplatin and (then) cisplatin, 
both at 1 mM, to immobilized HEWL in the presence of 20 mM sodium citrate buffer at pH 
4.4 (see experimental section for further details). 
 
 
 
 
Table 4 Equilibrium dissociation constants (KD) and kinetic parameters for the interaction 
of HEWL with cisplatin and oxaliplatin obtained using SPR method. 
This experiment, performed using a Pt complex concentration of 1 mM 
and 20 mM sodium citrate buffer at pH 4.4 as running buffer, shows an 
increase of Resonance unit (RU) signal after the injection of the second 
Pt complex. This finding clearly indicates that the two metallodrugs bind 
different sites on the HEWL surface. To further corroborate these results, 
thermal shift assays were carried out. In particular, we employed circular 
dichroism to determine the melting temperature of HEWL alone and in the 
presence of the two Pt complexes. In figure 15, the overlay of 
denaturation profiles of the wild type protein, of its adducts with cisplatin 
and oxaliplatin and of the bis-adduct formed using different strategies is 
reported. In particular, for the formation of the bis-adduct the two drugs 
are concomitantly added to HEWL (HEWL/cisplatin+oxaliplatin), or added 
to the protein at different times, i.e. first adding cisplatin and then 
oxaliplatin (HEWL/cisplatin then oxaliplatin) or vice-versa 
(HEWL/oxaliplatin then cisplatin). The comparison of Tm values points 
out that the cisplatin binding does not significantly alter the HEWL thermal 
stability, whereas oxaliplatin binding slightly decreases the protein melting 
Ligand 
 
kon 
(M-1s-1) 
koff 
  
(s-1)
         
KD 
(mM)   
Cisplatin 9.4 0.0173 1.83 ± 0.03 
Oxaliplatin 16.9 0.0256 1.51 ± 0.02 
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temperature. The formation of the bis-adduct, which seems to be afforded 
following different strategies, can be well evidenced by comparing melting 
temperatures of the different protein complexes examined (Table 5).  
 
 
Figure 15 Unfolding curves of HEWL and HEWL/Pt complexes as followed by monitoring 
the variation of molar ellipticity at 222 nm as function of temperature. Experiments have 
been performed using 20 µM protein or protein adduct in 10 mM sodium acetate buffer at 
pH 4.4. 
 
 
 
 
 
 
 
 
Table 5 Denaturation temperatures determined by Circular Dichroism spectroscopy for the 
protein-Pt complex adducts formed upon the interaction of HEWL with cisplatin and 
oxaliplatin in 10 mM sodium acetate buffer at pH 4.4. 
 
 
 
 
 
Complex Tm (°C) 
HEWL 77.2±0.1 
HEWL/cisplatin 76.5±0.5 
HEWL/oxaliplatin 
bis-adducts: 
73.0±0.1 
 
HEWL/cisplatin+oxaliplatin 
HEWL/cisplatin then oxaliplatin 
HEWL/oxaliplatin then cisplatin 
 
74.3±0.3 
74.0±0.1 
73.8±0.5 
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3.1.3.3 Discussion and conclusions 
In conclusion, unambiguous evidence is provided here that cisplatin and 
oxaliplatin can be used in combination to produce a bis-metalated HEWL 
adduct where a [Pt(NH3)]2+ fragment is bound to His15 and an 
oxaliplatin/[Ptdach]2+ fragment is bound to Asp119. The results of our 
experiments suggest that the two drugs manifest similar affinities for the 
protein, at least under the investigated experimental conditions, and that 
thermal shift analysis can be used to reveal the formation of the protein-Pt 
complex adducts. Obviously, the conditions required for the crystallization 
and the model protein used do not allow to obtain conclusions that are 
relevant for clinical cancer treatments. However, although the 
combination of drugs acting synergistically can offer a means of 
overcoming drug resistance,67-68 the results of our analysis suggest that in 
principle combination treatment of Pt drugs can possibly lead to a greater 
array of  side effects than previously imagined as different protein sites 
may be damaged. Also it can be highlighted and confirmed, as the two 
drug with similar pharmacological effects (i.e. cisplatin and carboplatin), 
form the same adduct with protein; instead oxaliplatin well known to 
possess pharmacological effect rather different from cisplatin and 
carboplatin, forms a different adduct that has been here described. 
3.1.3.4 Experimental section 
ESI-MS experiments 
cisplatin and oxaliplatin (3.0 x 10-4 M) were incubated for 24 h with 
lysozyme (10-4 M) in ammonium acetate buffer pH=6.8 at 37 °C. After a 
20-fold dilution with water, ESI-MS spectra were recorded by direct 
introduction at 5 μl min-1 flow rate in an Orbitrap high-resolution mass 
spectrometer (Thermo, San Jose, CA, USA), equipped with a 
conventional ESI source. The working conditions were the following: 
spray voltage 3.1 kV, capillary voltage 45 V, capillary temperature 220°C, 
tube lens voltage 230 V. The sheath and the auxiliary gases were set, 
respectively, at 17 (arbitrary units) and 1 (arbitrary units). For acquisition, 
Xcalibur 2.0. software (Thermo) was used and monoisotopic and average 
deconvoluted masses were obtained by using the integrated Xtract tool. 
For spectrum acquisition, a nominal resolution (at m/z 400) of 100,000 
was used. 
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Crystallization, Data collection and refinement 
cisplatin, oxaliplatin and hen egg white lysozyme (HEWL) were 
purchased from Sigma chemicals and used without further purification. 
Stock solution of HEWL was obtained dissolving the protein at a 
concentration of about 40 mg x mL-1 in 5 mM sodium acetate buffer at pH 
5 and stored at 4 °C. cisplatin and oxaliplatin solutions were freshly 
prepared for each experiment. 
Crystals of the bis-adduct have been obtained following two different 
protocols. Firstly, a protein sample has been first incubated for 24 h in the 
presence of an excess of oxaliplatin (protein to metal drug ratio 1:10) and 
then for 24 h in the presence of an excess of cisplatin (protein to metal 
drug ratio 1:10). Secondly, a protein sample incubated for 24 h in the 
presence of an excess of oxaliplatin (protein to metal drug ratio 1:10) has 
been mixed to a protein sample incubated for the same time in the 
presence of an excess of cisplatin (protein to metal drug ratio 1:10). 
Crystals of the bis-adduct were grown by hanging-drop vapor diffusion 
technique at 298 K mixing this sample containing 15 mg x mL-1 of HEWL 
incubated for a total of 48 h with the two metallodrugs with equal volumes 
of reservoir solution. Best crystals grow within 2-10 days from the 
following conditions: 0.6 M NaNO3, 0.1 M sodium acetate pH 4.4 and 20 
% ethylene glycol. Attempts to obtain crystals of the bis-adduct mixing the 
protein to a mixture of cisplatin+ oxaliplatin or adding first cisplatin and 
then oxaliplatin to the protein sample failed. In these cases we obtain 
crystals of the adduct between HEWL and cisplatin alone, i.e. structures 
of HEWL with Pt centre only bound to His15. 
X-ray diffraction data were collected from single crystals at the CNR 
Institute of Biostructure and Bioimages, Naples, Italy, using a Saturn944 
CCD detector equipped with CuKα X-ray radiation from a Rigaku 
Micromax 007 HF generator. Crystals were slowly dehydrated at air42 and 
flash-frozen at 100 K using nitrogen gas produced by an Oxford 
Cryosystem (and maintained at 100 K during the data collection) without 
using cryoprotectants, following the procedure used in other works.69-70 
Data set was processed and scaled using the HKL2000 package.45 Data 
collection statistics are reported in Table 6. 
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Table 6 Data collection and refinement statistics. 
The structures were solved by molecular replacement method, using the 
PDB file 4J1A,22 without water molecules and ligands, as starting model. 
The refinement was carried out with Refmac5.7,71 model building and 
map inspections were performed using Wincoot.47 5% of the data was 
used for calculation of the R-free value. After several rounds of 
refinement using the maximum likelihood option in Refmac, manual 
adjustments of side-chain atoms and addition of water molecules to the 
coordinates, the structures converged to Rfactor of 0.155/0.159 and to 
Rfree of 0.218/0.230. Refinement statistics are reported in Table S1. 
Structure validations have been carried out using Procheck.48 
 Bis-adduct1 Bis-adduct2 
PDBcode 4ZEE 4Z46 
DataCollection   
Spacegroup P43212 P43212 
Unit-cellparameters   
a,b,c(Å) 77.377,77.377,37.600 77.318,77.318,37.325 
Moleculespera.u. 1 1 
Resolution(Å) 54.71-1.95(1.98-1.95) 54.67-1.85(1.88-1.85) 
Observed reflections 47779 58591 
Uniquereflections 8452 10100 
Completeness(%) 95.8(83.2) 99.4(92.2) 
R merge 0.113(0.611) 0.095(0.471) 
I/σ(I) 11.7(2.3) 13.8(2.2) 
Multiplicity 5.7(4.3) 5.8(3.1) 
Refinement   
Resolution(Å) 54.71-1.95(1.98-1.95) 54.67-1.85(1.88-1.85) 
Number of reflections in working set 8023 9585 
Number of reflections in test set 403 482 
Rfactor/Rfree(%) 15.8/23.0 15.5/21.8 
Number of non-H atoms used in the 1209 1210 
Occupancy of Pt ions 0.40,0.35 0.40,0.35 
B-factor of Pt ions (Å2) 55.8,63.6 52.5,67.0 
OverallB-factor 27.6 26.8 
R.m.s.d.bonds (Å) 0.019 0.019 
R.m.s.d.angles (Å) 1.94 1.94 
Estimated overall coordinate errors(Å) 0.148 0.196 
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Coordinates and structure factors of the two structures were deposited in 
the Protein Data Bank (PDB codes 4Z46 and 4ZEE). 
For further details on surface plasmon resonance (SPR) and circular 
dichroism thermal denaturation experiments, see supplementary material.  
3.1.4  Cisplatin, carboplatin and oxaliplatin bind to RNase: studies of 
interaction and mechanistic hypothesis 
 
3.1.4.1 Introduction 
 
To gather further details in the reactivity of clinically used Pt drugs with 
proteins we have studied their interactions with RNase.  
In a recent paper, the structure formed in the reaction of RNase with 
cisplatin has been reported.37 This structure, shows as platinum(II) 
binding takes place exclusively at the level of Met29. These data have 
been compared with those obtained for carboplatin and oxaliplatin. ESI-
MS measurements are nicely supported by crystallographic structures 
and obtained results are an independent confirmation of the results 
presented in the previous sections; furthermore, on the basis of the 
available data, a likely mechanism for oxaliplatin hydrolysis and binding to 
the protein is proposed.  
 
3.1.4.2 Results 
 
Crystallography 
The structures of RNase A-carboplatin and RNase A-oxaliplatin have 
been solved at 2.09 and 2.27 Ǻ resolution, respectively. The overall 
structures of the two adducts are reported in figure 16B and 16C. The 
structures have been refined to Rfactor=20.5 and 22.4 (Rfree=26.2 and 
30.1), for the RNase A complexes with carboplatin and oxaliplatin, 
respectively. In both structures, the electron density maps of protein 
regions are rather well defined, with exceptions consisting of a few 
portions in both the molecules present in the asymmetric unit (molecule A 
and B, hereafter) of the two complexes. Similarly to what found for the 
RNase A-cisplatin complex (Figure 16A),37 in both RNase A-carboplatin 
and RNase A-oxaliplatin adducts platination does not affect the overall 
conformation of the protein, which remains very similar to the wild-type 
(CA root mean square deviations in the range 0.36-0.60 Å). 
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C          
 
Figure 16 Ribbon representation of the asymmetric unit of the RNase A-cisplatin (panel 
A), RNase A-oxaliplatin (panel B) and RNase A-carboplatin (panel B) structures. The 
molecules A and B are coloured in cyan and purple, respectively. Side chains of residues 
involved in the Pt drugs recognition are shown along with Pt centres. In panel B and C, 
2Fo-Fc electron density maps are coloured in red and contoured at 4σ. The structures of 
RNase A-oxaliplatin and RNase A-carboplatin have been deposited in the Protein Data 
Bank with entry codes 4S18 and 4S0Q. The structure of RNase A-cisplatin was already 
solved and deposited in the PDB with entry code 4OT4. 
 
As previously found for cisplatin37 and chloroplatinite (PtCl42−),73 the 
RNase A-carboplatin interaction in both A and B molecules mainly occurs 
at the SD atom of the side chain of Met29. However, due to unclear 
electron density maps likely associated with low occupancy and to the 
possible conformational disorder of this site, the local environment of the 
bound Pt(II) center, in the RNase A-carboplatin adduct, could not be 
unambiguously determined (Figure 17A and B). The refinement of B-
factors of Pt ligands and the inspection of residual Fo-Fc electron density 
maps suggests that the Pt ions have occupancy= 0.50 and 0.35 for 
molecule A and B, respectively. In both these chains, platination of Met29 
induces a disordering of residue 16-22 and of Tyr25 side chain.  
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A  B  
 
Figure 17 Details of the binding sites of Pt(II) in the RNase A-carboplatin adduct. Pt ion is 
bound to Met29 in the molecule A (panel A) and B (panel B). Asp14 side chain is included 
in the figure, since it is involved in the recognition of oxaliplatin (see below). 2Fo-Fc 
electron density maps are contoured at 0.8σ level (grey) and 4.0σ level (red). 
 
Although crystals of RNase A-oxaliplatin diffract to a resolution slightly 
lower than that obtained for RNase A-carboplatin and RNase A-cisplatin37 
complexes, the electron density maps clearly reveal details of the binding. 
In the RNase A-oxaliplatin structure, six Pt binding sites have been 
identified, i.e. three binding sites for each molecule of the asymmetric 
unit. 
In the main oxaliplatin binding site, the Pt(II) ion is bound to ND1 atom of 
His119 (Figure 18A and B). In this site, the electron density map is well 
defined and clearly shows that oxaliplatin retains the dach ligand upon 
binding to the protein. A water molecule complete the coordination sphere 
of the Pt centre. Retention of the dach ligand of oxaliplatin is observed 
during binding to model peptides in other studies.79 These results are also 
in line with the experimental observation by Shoeib and coworkers that β-
alanyl-L-histidine dipeptide (carnosine) is able to bind oxaliplatin inhibiting 
its cytotoxic action.79 Notably, the occupancy factor for the oxaliplatin 
fragment is = 0.8 in both A and B chains, but its orientation is different in 
the two molecules: indeed, the dach moiety is exposed to the solvent in 
molecule A, whereas it orients toward the active site in molecule B. In 
both cases, an extensive network of hydrogen bonds stabilizes the 
binding. 
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In the second binding site (Figure 18C and D), the Pt(II) ion is coordinated 
to SD atom of Met29, as for RNase A-cisplatin37 and RNase A-carboplatin 
adducts. Furthermore, in both molecules A and B, beyond the SD atom of 
Met29, Pt also coordinates to OD2 atom of Asp14. Residual Fo-Fc 
electron density map in this site indicates a possible variability in the 
anchoring mode of oxaliplatin also close to Met29 and Asp14 side chains. 
Platination induces a disordering of residues 16-23 in molecule A and 18-
21 in molecule B. The occupancy factor for the oxaliplatin fragment 
(Figure 18C and D) in this site is = 0.4 in molecule A and = 0.6 in 
molecule B. The relatively low occupancy of the oxaliplatin fragment in 
molecule A does not allow the modelling of the dach moiety (Figure 18C). 
Finally, a minor binding site has been observed close to His105 (Figure 
18 E and F). In this site only the Pt atom with occupancy = 0.20 has been 
modelled.  
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A         B    
C                      D  
E                      F  
 
Figure18 Details of the binding sites of Pt(II) in the RNase A-oxaliplatin structure. The 
drug is bound to protein through a coordinative interaction with side chain of His119 (panel 
A and B for molecules A and B, respectively). The [Ptdach]2+ fragment is involved in a 
number of hydrogen bonding interactions with water molecules that form an intricate 
network stabilizing the structure. Furthermore, Pt ion is bound to Met29 and Asp14 side 
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chains (panel C and D for molecules A and B, respectively). Oxaliplatin binding to sulfur 
atoms of physiologically important molecules like glutathione has been already observed 
in other studies.79 Finally, a minor Pt binding site has been identified close to side chain of 
His105 (panel E and F for molecules A and B, respectively). 2Fo-Fc electron density maps 
are contoured at 0.8σ level (grey) and 4.0σ level (red). Molecule A is coloured in cyan and 
molecule B in purple. In panels C, E and F only the atoms included in the final models are 
reported, for this reason in panel C some atoms of dach fragment are omitted, whereas in 
panels E and F only the Pt atoms are reported. 
Electrospray mass spectrometry 
A further  validation of the proposed RNase A-Pt ligation patterns and of 
the above interpretation of the electron density maps was achieved by 
performing independent ESI-MS measurements on Pt drug-protein 
adducts according to the established experimental procedure developed 
in our laboratory (see experimental section and Figure 19). ESI-MS 
spectra were recorded for RNase A-oxaliplatin (Figure 19A), RNase A-
carboplatin (Figure 19B), and also for RNase A-cisplatin adducts (Figure 
19C).  
Inspection of mass spectrometry results provides evidence for the 
formation of a variety of Pt adducts of different nature, in considerable 
amounts. 
In all cases, monometalated adducts are preferentially formed, though 
appreciable amounts of bis metalated derivatives are seen, especially in 
the case of oxaliplatin.  
Oxaliplatin forms, at first, two kinds of derivatives, of mass 13988.3 and 
14078.3 Da, in comparable amounts, assignable respectively to bidentate 
and monodentate species (Figure 19A); with time, the relative abundance 
of the bidentate adduct become higher and predominant on monodentate 
adduct, with associated release of oxalate ligand. In analogy with 
oxaliplatin, carboplatin (Figure 19B), first, forms a predominant 
monodentate derivative; for longer incubation times the cyclobutane-1,1-
dicarboxylate ligand (CBD) is progressively released and a peak 
assignable to the bidentate adduct increases in intensity. Though of low 
intensity, a peak falling at 14423.4 Da, is representative for bis-adduct 
formation.    
Comparative analysis of peak intensities for the metal-protein adducts 
suggests that oxaliplatin and cisplatin (Figure 19C) are far more reactive 
than carboplatin, although differing ionization efficiencies may also be a 
contributing factor. 
Protein metalation by conventional Pt-based anticancer drugs 
 
 
61 
 
A  
B  
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C  
Figure19 Deconvoluted ESI-MS spectra of RNase A treated respectively with 3*10-4 M of 
oxaliplatin (panel A), carboplatin (panel B) and cisplatin, (panel C) recorded after 24h (A), 
72h (B), 168h (C) of incubation at 37 °C. Experimental conditions: Metal:protein ratio = 
3:1; buffer: 20 mM ammonium acetate pH 6.8. 
3.1.4.3 Discussion and conclusions 
We have reported here the X-ray structures of the RNase A-carboplatin 
and RNase A-oxaliplatin adducts. As the crystal structure of the RNase A-
cisplatin had been previously solved,37 we are in the fortunate position 
that structures are now available for RNase A adducts with the three main 
Pt drugs; this allows making instructive structural comparisons. Notably, 
such an analysis is carried out using structures obtained by soaking 
metallodrugs into pre-existing isomorphous RNase A crystals grown 
under very similar conditions. The finding that the RNase A crystals 
contain two molecules in the asymmetric unit adds an internal validation 
to our results. Moreover, the crystallographic investigation has been 
nicely complemented by ESI-MS data on the same adducts which support 
the correct identification of the Pt species bound to the protein. The 
importance of using two independent biophysical methods such as X-ray 
crystallography and ESI-MS on the same system is thus further 
documented40b,40e and underscored. In particular, ESI-MS data turn very 
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valuable in elucidating the nature of protein bound platinum fragments for 
the RNase A-carboplatin adduct where crystallographic data are 
ambiguous, whereas X-ray diffraction data add molecular details on the 
binding of oxaliplatin to the protein. The results of this comparative 
structural analysis are summarized in table 7. On the basis of the 
reported data, the following considerations can be done: 
 cisplatin and carboplatin behave in a similar way, as they both 
produce, under the applied experimental conditions, a 
monometalated protein derivative where the Pt ion of the drug 
fragment mainly coordinates to SD atom of Met29. The platinum 
fragment coordinated to Met29 is distinct for the two drugs: it is 
[Pt(NH3)2]2+ for cisplatin and [Pt(NH3)2CBD] for carboplatin. 
Analyzing the metal binding site of carboplatin and cisplatin in 
detail, minor differences are observed that are probably due to the 
different steric hindrance of the Pt ligands. In the molecule B of 
the RNase A-cisplatin adduct,37 Pt can coordinate both SD atom of 
Met29 and NE atom of Gln28 (bidentate interaction),37 whereas 
only a monodentate interaction with Met29 seems to occur for 
carboplatin. Notably, ESI-MS results performed after a long 
incubation time point out that the CBD ligand may be released, so 
that a type of Pt fragment identical to that arising from cisplatin is 
eventually associated with the protein, and that a dimetalated 
adduct can also be formed. In addition, it must be stressed that 
cisplatin shows a greater reactivity than carboplatin in terms of 
amounts of formed derivatives as well witnessed by ESI-MS 
results. 
 
 Oxaliplatin also binds Met29, but it coordinates RNase A through 
interaction of a [Ptdach]2+ fragment. Furthermore, a bidentate 
coordination is observed that involves the OD1 atom of Asp14. 
The result confirms previous observations obtained with HEWL in 
which coordination of the [Ptdach]2+ cation selectively occurs at 
the level of the free carboxylate group of Asp residues.51 ESI-MS 
data suggest that the binding of oxaliplatin to the protein could 
occur according to a two-step process. Combining our data with 
the mechanism proposed for the acid hydrolysis of oxaliplatin,81,82 
a picture of the RNase A-oxaliplatin recognition can be drawn: the 
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oxalate ligand of Pt is detached in two consecutive steps, which 
involve the formation of oxalate monodentate complex. The ring-
opening step allows the replacement of oxalate with the 
carboxylate from the Asp residue (Figure 20). Ring-opened Met 
adducts of carboplatin have been studied previously.83 Since the 
formation of hydrolysis product species has been observed in 
vivo, this mechanism could be operative also under physiological 
conditions.81,82 
 
Pt drug 
RNase A 
binding sites 
as revealed 
by X-ray 
structural 
analysis of 
the adducts 
obtained by 
soaking 
procedure* 
N° of 
binding 
sites 
Binding 
mode 
suggested by 
X-ray 
structural 
analysis 
Drug Fragment 
suggested by X-ray 
structural analysis 
Drug Fragment 
as revealed by 
ESI MS 
cisplatin** 
   
Mol A: Met29 
Mol B: Met29, 
Gln28 
1 
 
monodentate 
bidentate 
 
[Pt(NH3)H2O]2+ 
[Pt(NH3)2]2+ 
 
[Pt(NH3)Cl]+ 
[Pt(NH3)2]2+ 
carboplatin 
 
Mol A: Met29 
Mol B: Met29 
1 monodentate 
monodentate 
undefined 
undefined 
 
[Pt(NH3)2]2+ 
[Pt(NH3)2CBD] 
2[Pt(NH3)2CBD] 
oxaliplatin 
 
Mol A:  His119   
Met29, Asp14    
His105 
 
Mol B:  His119 
Met29, Asp14    
His105 
3 monodentate 
bidentate 
monodentate 
monodentate 
bidentate 
monodentate 
[Pt(dach)(H2O)]2+ 
[Pt(dach)]2+ 
undefined 
[Pt(dach)(H2O)]2+ 
[Pt(dach)]2+ 
undefined 
 
Oxaliplatin 
[Pt(dach)]2+ 
Oxaliplatin 
+[Pt(dach)]2+ 
2[Pt(dach)]2+ 
 
Table 7 Structural features of Pt-drug binding sites from the X-ray structures of the 
adducts obtained by soaking procedure on C2 crystals of RNase A and by ESI-MS data. 
*from ref. 37 
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** It is interesting to note that all RNase A residues involved in the three platinated 
adducts (Asp14, Gln28, Met29, His105 and His119) are conserved in the human 
pancreatic enzyme (HP-RNase). 
 
         
Figure 20 Proposed mechanism for oxaliplatin hydrolysis and binding to Met29 and Asp14 
residues of RNase A. The bidentate adduct formation proceeds through ring opening and 
initial formation of a monodentate intermediate. 
Notably, in the RNase A-oxaliplatin adduct, other Pt binding sites are also 
detected. In the main binding site, Pt coordinates the ND1 atom of 
His119. Furthermore, oxaliplatin can also bind, with low occupancy, the 
NE2 atom of His105. These results are interesting since it has been 
previously shown, by studying its interaction with HEWL, that oxaliplatin 
preferentially binds Asp side chains,51 while both carboplatin and cisplatin 
show a preference for His side chains.36a,84 This is even more surprising if 
one takes into account that the oxaliplatin fragment bound to RNase A is 
larger than those of carboplatin and cisplatin. These results could be 
explained by considering the kinetics of the protein-metallodrug 
recognition. In fact, it has been shown that, contrary to its DNA binding 
capacity, the rate of protein binding of oxaliplatin may be significantly 
higher than that of cisplatin and carboplatin.31,85 On the other hand, these 
data also agree with previous crystallographic findings on the adduct 
formed in the reaction between trans-Pt derivatives and RNase A.53 It 
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should be also noted that cisplatin has been found to bind both His105 
and His119 in RNase A-cisplatin crystals of a different space group and 
obtained under different crystallization conditions.75 In this respect, we 
cannot exclude that carboplatin could be able to bind His105 and His119, 
using the approach described in reference 75 or after longer soaking 
time. 
The results of this comparative structural analysis suggest that cisplatin 
and carboplatin behave similarly when they react with proteins, while 
oxaliplatin shows a significantly different behavior. We suggest that 
differences in reactivity and adduct formation with proteins, which could 
be related to a different kinetics of metallodrug-protein binding, may have 
a more general significance and may be at the basis of the different 
pharmacological and toxicological profile of the three drugs. Altogether 
these data support previous hypotheses that metal ligands play a key role 
in the protein-metallodrug interactions, driving the drug-biological target 
recognition and stabilizing the structure of the final adduct.86 The binding 
of cisplatin, carboplatin and oxaliplatin to Met appears also interesting if 
one considers that Pt binding to S-donor ligands, including methionine 
and glutathione, occur in physiological conditions and that it plays a 
relevant role in the Pt-drugs metabolism. S-donor binding of Pt-drugs was 
suggested to be involved as an intermediate in transport to the DNA in 
nucleus.86,89 Finally, our data point out that the three Pt drugs mainly bind 
proteins through formation of monodentate (like carboplatin or cisplatin in 
molecule A)37 or bidentate (like oxaliplatin, or cisplatin in molecule B)37 
derivatives.  
Before binding, the Pt complex needs to be activated. Activation consists 
of the release of labile ligands: two chlorides in the case cisplatin, the 
cyclobutandicarboxylate ligand in the case of carboplatin; oxalate in the 
case of oxaliplatin. The activation process and the consequent protein 
metalation may manifest a large kinetic variability depending on the 
nature of the leaving group and on the possible “assistance” offered by 
the protein. 
 
3.1.4.4 Experimental section 
 
Crystallization, Data collection and refinement 
 
Oxaliplatin, carboplatin and RNase A (type XII-A), sodium citrate and 
PEG4K were obtained from Sigma. Crystals of the RNase A adducts 
were obtained by soaking experiments where pre-grown monoclinic 
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protein crystals were incubated with an excess of the platinum drug (at a 
protein to platinum ratio 1:10). This procedure has been already used to 
obtain crystals of productive complexes of RNase A including that with 
cisplatin37 and other metallodrugs.53,76,77 Briefly, the crystals of RNase A 
were grown as previously described37,53,76,77 by hanging-drop vapor mixing 
1 µL of RNase A at 20 mg mL-1 with equal volumes of reservoir solution 
containing 20% PEG4000 and 20 mM sodium citrate buffer pH 5.0 at 298 
K. Two weeks after their appearance, crystals have been soaked for four 
days in a solution of carboplatin or oxaliplatin dissolved in 10 µL of 
reservoir. Final Pt drugs:protein concentration ratios were 10:1. 
X-ray diffraction data have been collected from single crystals at the CNR 
Institute of Biostructure and Bioimages, Naples, Italy, using a Saturn944 
CCD detector equipped with CuKα X-ray radiation from a Rigaku 
Micromax 007 HF generator. Crystals have been flash-frozen at 100 K 
using nitrogen gas produced by an Oxford Cryosystem (and maintained 
at 100 K during the data collection) without using cryoprotectants, 
following the dehydration procedure42 already used in many other 
works.40c,69,70 Data sets were processed and scaled using the HKL2000 
package.45  Although the soaking significantly affects the quality and the 
diffraction power of RNase A crystals, X-ray diffraction data have been 
collected at 2.09 Å and 2.27 Å resolution for carboplatin and oxaliplatin, 
respectively. Attempts to improve the resolution collecting datasets on 
crystals soaked with Pt drug with a reduced time of soaking (up to 5 
hours) leads to acquisition of data corresponding to ligand-free RNase A. 
Data collection statistics are reported in table 8. The structures have been 
solved by molecular replacement method, using the PDB file 1JVT,78 
without water molecules and ligands, as starting model. The refinement 
was carried out with Refmac5,46 model building and map inspections were 
performed using Coot.47 5% of the data was used for calculation of the R-
free value. The initial 2Fo-Fc and Fo-Fc electron density maps clearly 
indicated the position of Pt ions. The binding of carboplatin induces the 
disordering of residues 16-22 and of the Tyr25 side chains, which are not 
included in the final model. The binding of oxaliplatin induces disordering 
of residues 16-23 in molecule A, 18-21 in molecule B and of Gln28 side 
chain. In this last structure residues 16-23 in molecule A and residues 18-
19 in molecule B have been omitted from the final model, the other 
disordered residues (residues 16-17 and 20-21 of molecule B) are fitted in 
a poor electron density Refinement statistics are reported in table 8. 
Structure validation has been carried out using Procheck.48 Coordinates 
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and structure factors for the adducts have been deposited in the Protein 
Data Bank (PDB codes 4S0Q and 4S18). 
 
    RNase A-Carboplatin  RNase A-Oxaliplatin 
PDB code    4S0Q   4S18 
Data-collection    
Space group   C2*   C2* 
Unit cell parameters 
a,b,c (Å)    100.52, 32.50, 72.71  100.72, 32.74, 73.23 
β (°)    89.59   90.36 
Molecules per asymmetric unit  2   2 
Observed reflections   78969   70667 
Unique reflections   14095   10764 
Resolution (Å)   50-2.09 (2.14-2.09)  50-2.27 (2.29-2.27) 
Completeness (%)   99.7 (100.0)  95.4 (93.8) 
Rmerge†    0.124 (0.672)  0.161 (0.718) 
I/σ(I)    12.0 (3.0)   10.5 (2.6)  
Multiplicity     5.6 (5.6)   6.6 (5.1) 
Refinement 
Resolution (Å)    30.9-2.09   50.0-2.27 
number of reflections in working set  13380   10237 
number of reflections in test set   709   520 
R factor/Rfree (%)    0.205 (0.262)  0.224(0.301) 
Number of non-H atoms used in the refinement    1948   1935 
Occupancy of Pt ions                      0.50/0.35    0.40/0.60    0.80/0.80      0.20/0.2* 
 
B-factor of Pt ions      65.5/66.7  55.4/52.9/51.6/55.3/55.6/60.9 
Overall B-factor      37.8   46.4 
Deviations from ideality values 
R.m.s.d. bonds(Å)      0.016   0.012 
R.m.s.d. angles(Å)      1.76   1.96 
*
 
for Met29/Asp14,His119 and His105 binding sites in the A and B chains
 
 
Table 8 Data collection and refinement statistics for the RNase A-carboplatin and RNase 
A-oxaliplatin structures. 
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ESI-MS experiments 
 
A solution of cisplatin, carboplatin or oxaliplatin with RNase A (10-4 M) (3:1 
metal/protein ratio) in 20 mmol L-1 ammonium acetate pH 6.8 was 
incubated at 37°C for one week and ESI-MS spectra were recorded after 
24, 72 h and one week. After a 20-fold dilution with water, ESI MS spectra 
have been recorded by direct introduction at 5 μl min-1 flow rate in an 
Orbitrap high-resolution mass spectrometer (Thermo, San Jose, CA, 
USA), equipped with a conventional ESI source. The working conditions 
were the following: spray voltage 3.1 kV, capillary voltage 45 V, capillary 
temperature 220°C, tube lens voltage 230 V. The sheath and the auxiliary 
gases were set, respectively, at 17 (arbitrary units) and 1 (arbitrary units). 
For acquisition, Xcalibur 2.0. software (Thermo) was used and 
monoisotopic and average deconvoluted masses were obtained by using 
the integrated-Xtract tool. For spectrum acquisition, a nominal resolution 
(at m/z 400) of 100,000 was used. 
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4.1 Introduction 
It was long believed that iodido analogues of classical anticancer 
platinum(II) compounds should be poor pharmacological agents, their 
inactivity being ascribed to the greater stability and lower reactivity of Pt-I 
bonds as compared to Pt-Cl bonds in aqueous solution.1-3 Moreover, early 
studies on cis-PtI2(NH3)2 reported it to be inactive as an anticancer agent 
in an animal model.4 These considerations greatly hampered the further 
development of iodidoplatinum complexes as experimental anticancer  
agents. However, a few subsequent studies highlighted a considerable 
and unexpected reactivity for iodido Pt(II) and Pt(IV) complexes5 toward 
important biomolecular targets (e.g. serum albumin and glutathione).6,7  
For the reasons reported above it is important to reconsider in more depth 
iodidoplatinum complexes as a source of new anticancer agents, for 
which there is still a wide margin for the development of new molecules 
with different chemical properties that could present innovative 
characteristics, and hopefully ability to overcome the limits of the 
conventional anticancer drugs. 
 
4.1.1 Peculiar features in the interaction between lysozyme and cis-
PtI2(NH3)2 
 
4.1.1.1 Introduction 
 
In chapter 3, we have shown as, through a comparative study of cisplatin, 
carboplatin and oxaliplatin, it is possible to find interesting differences in 
their interaction with model proteins. Remarkably, a tentative correlation 
between the differences in their protein metalation and their well known  
pharmacological effects, has been highlighted. Overall, cisplatin and 
carboplatin that have similar pharmacological effect, behave very 
similarly, while oxaliplatin, that possesses a quite different 
pharmacological characteristics, exerts its interaction with protein in a 
different manner. These considerations, lead us to investigate the 
reaction of iodido analogues of cisplatin, a family of potential anticancer 
drugs, overlooked so far, toward the model protein lysozyme. Although 
cisplatin remains one of the most effective chemotherapeutic agents for 
cancer treatment, recently, a number of cis and trans 
diaminediiodoplatinum compounds (such as cis-PtI2(ammine)2, trans-
PtI2(ammine)2) showing unconventional reactivity have been synthetized 
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and their cytotoxicity evaluated towards a number of human tumor cell 
lines.8,9 
As a model for the interaction of iodido analogues of platinum(II) drugs 
with proteins, and to compare directly results with cisplatin, the cisplatin 
analogue cis-PtI2(NH3)2, has been chosen to perform a detailed 
investigation of its reactions with HEWL by X-ray crystallography and ESI-
MS spectrometry. 
 
4.1.1.2 Results 
 
Crystals of the adduct between HEWL and cis-PtI2(NH3)2 have been 
obtained by soaking experiments where pre-grown HEWL crystals were 
incubated for two months with an excess of the platinum drug.  
These crystals were subject to X-ray diffraction data collection and the 
structure of the adduct could be solved at 1.99 Å resolution. Details of 
crystallization, data collection and structure refinement are given in the 
experimental section. The overall structure of the adduct between HEWL 
and cis-PtI2(NH3)2 (HEWL-cis-PtI2(NH3) adduct) (Figure 1), which refines 
to Rfactor=18.4 (Rfree=23.4), is very similar to that of the native protein 
(PDB code 193L): the root mean square deviation in positions of CA 
atoms is 0.3 Å. 
 
 
 
 
 
 
Figure 1 Ribbon representation of the structure of the adduct between HEWL and cis-
PtI2(NH3)2. The side chain of His15, which is solvent accessible, being situated on the 
protein surface, is shown along with Pt, ammonium and I ligands. For sake of clarity just 
one of the two different modes of binding of cis-PtI2(NH3)2 to HEWL is shown. The 
structure has been deposited in the Protein Data Bank under the accession code 4MR1. 
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In agreement with what found in the case of cisplatin by Casini et al.,10 
platination occurs at the ND1 atom of the imidazole ring of His15, i.e. at 
the right-handed site. The local environment of the protein bound Pt(II) 
center was identified by observation of a very clear electron density map 
(Figure 2). Notably, the Pt(II) ion is coordinated to ND1 atom of His15, to 
two I atoms and a N, in a classical square planar geometry. The 
refinement of temperature factors of Pt ligands and the inspection of 
residual Fo-Fc electron density maps indicate that two equivalent modes 
of Pt binding are present in the crystal structure, which differ only in the 
location of I atoms with respect to ND1 of His15 (Figure 3). The existence 
of two alternative modes of binding was further supported by inspection of 
the anomalous scattering map which confirmed the presence of 
anomalous signals of I and Pt atoms in the binding moieties (Figure S9 in 
the supplementary material). 
In the former mode of binding, the NH3 group is close to N and OD1 
atoms of Asn93 (distances 3.8 and 4.5 Å, respectively); in the latter, the 
NH3 group is solvent exposed and interacts with two water molecules, 
which, in turn are in contact with Arg14, whereas I atom occupies the 
position close to Asn93 (Figure 3A and 3B). Within these assumptions, 
His(N)-Pt distance is of 2.1 Å, whereas the Pt-I and Pt-N(NH3) distances 
are, on average, both close to 2.4  Å 
 
 
 
 
 
Figure 2 Details of the binding site of Pt(II) in HEWL-cis-PtI2(NH3)  showing the Pt ion 
bound to His15. 2Fo-Fc electron density maps are contoured at 1σ level. For sake of 
clarity just one of the two different modes of binding of cis-PtI2(NH3)2 to HEWL is shown. 
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A  B  
 
 
Figure 3 The two modes of binding of cis-PtI2(NH3)2 to HEWL. I atoms are coloured in 
purple, N atoms are coloured in blue. 
 
Remarkably, the present structure shows that the platinum(II) ion binds 
the protein with an occupancy value close to 1.0. To the best of our 
knowledge, this is the highest occupancy ever observed for Pt in adducts 
between proteins and cisplatin-like drugs. No other significant 
modifications of the electron density map were observed ruling out the 
presence of additional (secondary) binding sites. This finding supports the 
view that the interaction of cisplatin-like drug with HEWL is highly 
selective for His15. 
Independent valuable information on the same system was subsequently 
gained through application of ESI-MS (see experimental section). 
Electrospray ionization mass spectrometry is indeed a powerful and 
informative tool to characterise the interactions of metal based drugs with 
small model proteins. Precise information may be derived on the 
stoichiometry and kinetics of binding as well as on the exact nature of the 
protein bound metal fragments.9,11,12 HEWL dissolved in a suitable buffer 
(20 mM ammonium acetate buffer, pH 6.8) was treated with a 3:1 excess 
of a fresh solution of the study compounds and ESI-MS spectra 
measured after increasing time intervals. Deconvoluted ESI-MS spectra 
recorded at the indicated time intervals (6, 24, 48 and 72 h) are shown in 
figure 4. Progressive formation of adducts is well witnessed by the 
appearance of a number of peaks of higher molecular mass than the 
native protein. Interestingly, the dominant peak within those attributed to 
platinum adducts shows a value of 14769.63 Da, that perfectly matching 
the mass of an adduct where a single [PtI2NH3] fragment is bound to the 
protein. This observation offers further and independent support to the 
above reported crystallographic results. 
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Figure 4 . Deconvoluted ESI MS of HEWL treated with 10-4 M cis-PtI2(NH3)2 (metal:protein 
ratio = 3:1) in 20 mM ammonium acetate (pH 6.8) buffer recorded after 6h (A), 24h (B), 
48h (C), 72 h (D) of incubation at RT. 
 
4.1.1.3 Discussion and conclusions 
 
In conclusion we have provided here unambiguous structural evidence 
that the diiodido analogue of cisplatin forms stable protein adducts 
containing a different type of protein bound metal fragment. While 
cisplatin typically affords protein platination through coordination of a 
[Pt(NH3)2]2+ fragment to selected protein side-chains,10 cis-PtI2(NH3)2 
preferentially gives rise to a protein bound [PtI2NH3] fragment with full 
retention of the two halide ligands. This finding is of great interest 
implying that the diiodido analogue produces a type of biomolecular 
metalation remarkably distinct from that inferred by cisplatin. It would be 
interesting to verify if this kind of metalation is operative even toward 
double helix DNA. This might result in different patterns of DNA and 
proteins platination and, accordingly, in a different pharmacological 
profile. Thus, the present results highlight that the simple chloride to 
iodide replacement in cisplatin may have spectacular consequences on 
the reactivity and the biological actions of platinum(II) compounds and 
may lead to classes of innovative platinum compounds not obeying 
classical Hoeschele’s rules.4 
 
A 
B 
C 
D 
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4.1.1.4 Experimental section 
 
Synthesis of cis-PtI2(NH3)2 
 
cis-PtI2(NH3)2 was synthesized according to published procedures,  using 
(1:4) Pt:KI in order to avoid further purifications.8,13 The purity of the 
product was checked by elemental analysis of C, N and H [Calculated C: 
0%, H: 1,26%, N: 5,84%, Experimental: C: 0%, H: 1,12%, N: 5,71%.], and 
as described in ref. 14. The correct cis geometry was assessed by 
comparison with its trans analogue as describe in the literature.14,15 
 
Crystallization, Data collection and refinement 
 
HEWL crystals were grown at 293 K using the hanging drop vapour 
diffusion method. The reservoir (600 µL) contained 20 mM sodium 
acetate buffer at pH 4.2 and 1.0 M NaCl; the drop (0.5+0.5 µL) contained 
hen egg white lysozyme (10 mg mL-1) in the same acetate buffer (5mM) 
and reservoir solution. Crystals grow in 1 day. After 5 days, HEWL 
crystals were soaked for two months in a DMSO solution of cis-PtI2(NH3)2. 
Final concentration of the metal complex in solution was >10 times higher 
than HEWL. X-ray diffraction data were collected at the Institute of 
Biostructures and Bioimages using a Saturn944 CCD detector equipped 
with CuKα wavelength X-ray radiation from a Rigaku Micromax 007 HF 
generator at 100 K. Data were collected without cryoprotectant, using a 
procedure recently developed.16 This procedure partly dehydrates the 
crystals, enhancing in some cases the resolution of X-ray diffraction 
data.17 Data were processed using the program HKL2000.18 The structure 
was solved using the Fourier difference method and the structure of 
HEWL without ligands deposited in the Protein Data Bank with code 
4JS319 as starting model. The refinement has been performed using 
CNS.20 Model building and map inspections were performed using O.21 
The coordinates have been deposited in the Protein Data Bank (PDB) 
under the accession code 4MR1. Data statistics: space group, P43212; 
unit cell, 77.02 Å, 77.02 Å, 36.83 Å; Resolution range: 50–1.99Å; 
observed reflections (unique) = 14571 (743); I/σ(I) = 47.6 (1.9); 
completeness = 99.9 % (100%); Rmerge: 10.9% (71.0%). Values in 
parenthesis relate to the highest resolution shell (2.02–1.99 Å). 
Refinement: R-factor: 18.4%, R-free: 23.4%; rms bonds = 0.018Å, rms 
angles (°) = 3.82. 
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ESI-MS experiments 
 
A solution of cis-PtI2(NH3)2 (10-4 M) with HEWL (3:1 metal/protein ratio) 
was incubated at RT for 72 h and ESI MS spectra were recorded after 6, 
24, 48, 72 h. After a 20-fold dilution with water, ESI-MS spectra were 
recorded by direct introduction at 5 μl/min flow rate in an Orbitrap high-
resolution mass spectrometer (Thermo, San Jose, CA, USA), equipped 
with a conventional ESI source. The working conditions were the 
following: spray voltage 3.1 kV, capillary voltage 45 V, capillary 
temperature 220°C, tube lens voltage 230 V. The sheath and the auxiliary 
gases were set, respectively, at 17 (arbitrary units) and 1 (arbitrary units). 
For acquisition, Xcalibur 2.0. software (Thermo) was used and 
monoisotopic and average deconvoluted masses were obtained by using 
the integrated Xtract tool. For spectrum acquisition a nominal resolution 
(at m/z 400) of 100,000 was used. 
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4.1.2 Further insight into antineoplastic properties of cis-PtI2(NH3)2  
 
4.1.2.1 introduction 
 
As reported in paragraph 4.1, iodide analogues of cisplatin possess 
peculiar characteristic concerning their reactivity toward model protein 
with respect to cisplatin. It is also quite surprising that, despite the huge 
research efforts made on platinum analogues over the last three decades, 
only rare studies were carried out on cis-PtI2(NH3)2 (cisPtI2), the strict iodo 
analogue of cisplatin. Accordingly, even the cytotoxicity profile of cisPtI2  
against the 60 cancer cell lines panel of NCI has never been reported. 
Altogether, these arguments led us to reconsider, in a more systematic 
way, some key chemical and biological aspects of cisPtI2 with respect to 
cisplatin.  
Specifically, we have focused our attention on the four following issues : i) 
the activation process of cisPtI2 in aqueous solutions both at physiological 
and slightly acidic pH; ii) a computational rationalization of the spectral 
results;  iii) the investigation of the direct reaction of cisPtI2 with DNA; iv) 
the cellular effects of cisPtI2 in a small panel of cancer cell lines. Some 
notable results have emerged from these studies that are 
comprehensively analysed and discussed here in direct comparison to 
cisplatin, with relevant mechanistic and medical implications. 
 
4.1.2.2 Results 
 
Solution Chemistry of cis-PtI2(NH3)2:  logP determination and activation 
profile in aqueous buffers 
 
We first investigated some unexplored chemical features of cisPtI2; in 
particular we determined its logP value and analysed its solution 
behaviour under various conditions and the inherent metal complex 
activation processes.  
The logP of cisPtI2 was measured according to the method reported in the 
experimental section; a value of -0.13 was determined versus a value of -
2.4 previously determined for cisplatin and here again confirmed. This 
result implies that cisPtI2, in its intact form, is far more lipophylic than 
cisplatin: this might have some appreciable impact on its cellular uptake 
(see later). 
Then, the solution behaviour of cisPtI2 was studied spectrophotometrically 
under physiological-like or slightly acidic pH conditions. Remarkably, 
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freshly prepared aqueous solutions of cisPtI2, at pH=7.4, manifest two 
intense bands in the UV-visible region, located at 290 and 350 nm, 
respectively, that allow the direct and continuous monitoring of the 
solution behaviour of this platinum complex (Figure 5). 
 
 
 
Figure 5 time dependent UV-Vis analysis of complex cis-PtI2(NH3)2 10-4 M in 50 mM 
phosphate buffer (pH=7.4) followed for 72 h. 
 
Some important spectral changes are slowly detected consisting in the 
progressive and regular decrease of the two main bands and in the 
appearance of a new band, of lower intensity, around 280 nm. The 
observed spectral changes are tentatively traceable to the progressive 
release of the two iodido ligands and to their replacement by water 
molecules. This would mean that the aquation process of cisPtI2 
reproduces quite closely that of cisplatin, involving the progressive 
detachment of the two halide ligands while both ammonia ligands are 
kept as confirmed by some further experiments. In particular, addition of 
KI at increasing concentrations completely abolished and even reverted 
the above described spectral changes (see supplementary material) 
strongly supporting the proposed interpretation. In any case, the rate of 
the aquation process for cisPtI2 is appreciably  slower than for cisplatin 
(by at least a factor 2) possibly because of the greater strength of the Pt-I 
bond and/or greater inertness related to the increased "soft” character of 
iodide over chloride (more details for hydrolysis process and UV-Vis 
analysis are given in the supplementary material). 
To gain further insight into the activation processes of cisPtI2, we also 
analysed its spectral behaviour under slightly acidic conditions. Indeed, a 
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mildly acidic environment is thought to destabilise the ammonia ligands 
and thus favour ammonia release over iodide release. Accordingly, cisPtI2 
was dissolved in an acetate buffer, at pH 4.5, and its spectral changes 
monitored over 72 hours. The resulting spectral  profile is shown in figure 
6: it is apparent that the overall spectral profile is profoundly different from 
that recorded at physiological pH. In particular, a new and quite intense 
visible band is clearly detected around 410 nm, at 72 hours, whose 
assignment is discussed later. 
 
Figure 6 UV-Vis spectral  changes of complex cis-Pt I2(NH3)2 10-4 M in 50 mM, acetate 
buffer (pH=4.5) followed for 72h. Gray line t=0 h, red line t=72 h. 
Computational studies, simulation of UV-Vis spectra 
To interpret the reported spectral profiles at two distinct pH values, we 
performed UV-Vis spectra simulations of 5 species: the native cisPtI2, two 
products of the Iodido aquation mechanism i.e. [cis-PtI(H2O)(NH3)2]+ (1), 
[cis-Pt(H2O)2(NH3)2]2+ (2) and two products related to ammonia aquation 
mechanism i.e. [cis-PtI2(NH3)(H2O)] (3), [cis-PtI2(H2O)2] (4). 
The computed spectrum of cisPtI2 (cfr. red line in Figure 7a) is in very 
good agreement with the experimental one reported in figure 5. The 
calculated spectra for the mono- and di-Iodido hydrolysis species, i.e. (1) 
and (2), reproduce closely the experimental spectral evolution shown in 
figure 5, offering  strong support to the iodide release mechanism. 
Simulated bands assignments were done through transition density plots 
reported in figure 7b. It is possible to observe that, for cisPtI2, band A is a 
LMCT transition, I,O(px,y) →Pt(dx2-y2), while band B is a platinum d-d 
transition, Pt(dxy) → Pt(dx2-y2). Notably,  band A changes from a LMCT to 
a platinum d-d character passing from cisPtI2 to species (1) and (2). For 
(1), both bands have a Pt(dxy) → Pt(dx2-y2) character. For (2) we observed 
that (B) band observed for the cisPtI2 undergoes  a blue shift until it turns 
into band (A).  
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Band B conserved the Pt(dxy) → Pt(dx2-y2) character observed for (2). 
Such behavior is in agreement with expected d orbitals shifts due to 
substitution of a strong basic π donor as iodide with one water molecule. 
 
A        B   
Figure 7 (a) Evolution of UV-Vis spectral features for the Iodide hydrolysis mechanism. 
(b) Evolution of the electronic transition’s nature of A and B bands during the iodido 
aquation mechanism (cis-PtI2(NH3)2 top, [cis-PtI(H2O)(NH3)2]+ middle and [cis-
Pt(H2O)2(NH3)2]2+ bottom): for each transition red densities correspond to arrival orbitals 
and blue densities correspond to starting molecular orbitals. Platinum ions are coloured in 
silver, nitrogen in blue, oxygen in red, iodide in violet and hydrogen in white. 
To verify the correctness of the supposed iodide hydrolysis mechanism 
for physiological-like pH conditions, we have calculated the UV-Vis 
spectra (see Figure 8a) also for the species involved in the concurrent 
amino hydrolysis mechanism, i.e. (3) and (4).  In this case, the two cisPtI2 
bands undergo a significant red shift keeping their shape and relative 
intensities practically unchanged. Interestingly, the same behavior is 
experimentally observed for acidic conditions (cfr. Figure 6), where, 
indeed, the release of the ammonia ligands is expected. Furthermore, 
since dimeric species of the type [Pt(amine)I2]2, that are active on selected 
cancer cell lines, were reported to be synthesised in acidic conditions,34 
additional ESI-MS experiments were carried out at pH=4.5. Formation of 
dimers in solution under the latter conditions is confirmed by the presence 
of few weak peaks assignable to these species (see supplementary 
material). 
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A   B  
Figure 8 (a) Evolution of UV-Vis spectral features for the ammonia hydrolysis mechanism. 
(b) Evolution of the electronic transition’s nature of A and B bands during the ammonia 
aquation mechanism (cis-PtI2(NH3)2 top, [cis-PtI2(NH3)(H2O)] middle and [cis-PtI2(H2O)2] 
bottom): for each transition red densities correspond to arrival orbitals and blue densities 
correspond to starting molecular orbitals. Colour code as in Figure 7. 
The difference transitions MOs analysis performed for this second group 
of molecules is shown in Figure 8b; it is observed that the nature of the 
main spectral transitions is retained for all species involved. In this case, 
only the shift of valence molecular orbitals has been observed due to the 
similar orbital contributions of ammonia and water molecules. Therefore 
bands (A) and (B) can be described as I,O(px,y) → Pt(dx2-y2), Pt(dxy) → 
Pt(dx2-y2) transitions, respectively. 
 
DNA binding properties of cis-PtI2(NH3)2  
 
To determine the nature of the DNA interactions of cisPtI2, the DNA 
binding properties of this complex were examined through a variety of 
methods and compared with those of cisplatin. First, we aimed at 
quantifying the binding of cisPtI2 to mammalian (CT) double-helical DNA 
in a cell free medium. 
The amount of platinum bound to DNA increased with time and the times 
at which the binding reached 50% (t50%) are summarized in table 1.  
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Compound t50% (min)a 
cis-PtI2(NH3)2 aged in H2O 105 ± 11 
cisplatin aged in H2O   64 ± 5 
cis-PtI2(NH3)2 aged in 10 mM KI 390 ± 24 
cisplatin aged in 10 mM KCl 136 ± 19 
a
 The time at which the binding reached 50%. Values shown in the table are the means ± 
SEM of three separate experiments. 
Table 1  Binding of cis-PtI2(NH3)2 and cisplatin to calf thymus DNA. 
Importantly, after 24 h, cisPtI2 and cisplatin aged in water or in 10 mM 
KI/KCl were quantitatively bound. As expected, the PtII complexes 
preincubated in water reacted with DNA significantly more rapidly than 
those preincubated in KI/KCl (10 mM), but the rate of the reaction of 
cisplatin was considerably higher than that of cisPtI2. 
The lower rate of the reaction of cisPtI2 with double-helical DNA in 
comparison with that of cisplatin can be interpreted to mean22 that the rate 
of the aquation of the leaving ligands in cisPtI2 is significantly lower than 
that in cisplatin. Since interstrand and intrastrand cross-links formation 
are believed to be responsible for anticancer activity of bifunctional 
platinum compounds, we have quantitated the interstrand cross-linking 
efficiency of cisPtI2 in the linear pUC19 DNA (linearized with EcoRI 
restriction enzyme). Results point out that interstrand cross-linking 
efficiency of cisPtI2 (5 ± 2%) was similar to that of cisplatin (6 %) (see 
supplementary material for further details).23 
Afterward, to gain more information about the adducts formed in the 
reaction of cisPtI2 with DNA, in comparison with those produced by 
cisplatin, experiments with the fluorescent probe ethidium bromide have 
been carried out. Double helical DNA was first modified by the PtII 
complex (cisPtI2 or cisplatin) for 24 h. The levels of the modification 
corresponded to the values of rb in the range between 0 and 0.1. 
Modification of DNA by both platinum complexes resulted in a decrease 
of EtBr fluorescence (Figure 9). 
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Figure 9 Ethidium bromide fluorescence. Dependences of the EtBr fluorescence on rb for 
CT DNA modified by platinum complexes in 10 mM NaClO4 at 37 °C for 24 h. Open 
symbols, cis-PtI2(NH3)2; closed symbols, cisplatin. 
 
The formation of adducts of cisPtI2 resulted in a progressive decrease of 
EtBr fluorescence intensity, which was similar to that of cisplatin. This 
result suggests that the conformational distortion induced in DNA by the 
adducts of cisPtI2 is delocalized and extends over the same number of 
base pairs around the platination sites as in the case of the adducts of 
cisplatin. 
Even DNA unwinding experiment suggests the same mode of metalation 
between cisplatin and its iodide analogue (see supplementary material for 
further experimental details). Using this approach, we determined the 
DNA unwinding angles to be in the range 11 ± 2° for cisPtI2, which is very 
similar to that found for cisplatin (13°).24 Finally thermal stability 
experiment of DNA has been carried out. 
CT DNA was modified by cisPtI2 to the value of rb = 0.03–0.09. After the 
modification, the salt concentration was further adjusted by addition of 
NaCl to 0.1 M, and the samples were further supplemented by Tris-HCl (1 
mM) and EDTA (0.1 mM). Thus, the melting curves for DNA modified by 
the platinum compounds were measured at a relatively high salt 
concentration (Table 2). We found that the effect of DNA platination by 
cisPtI2 on the melting temperature of DNA (tm) is similar to that observed 
for the modifications by cisplatin.  
Three major factors have been invoked to account for the thermal stability 
of DNA modified by PtII complexes capable of DNA cross-linking and the 
observed change in melting temperature of DNA as a consequence of its 
platination reflects the relative proportion and contribution of these three 
factors.25  
These three factors are (i) a destabilizing effect of conformational 
distortions due to the formation of cross-links induced in DNA by platinum 
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coordination; (ii) stabilizing effects of DNA interstrand cross-links which 
prevent dissociation of DNA strands; (iii) the positive charge on the PtII 
centers (introduction of a positive charge into the DNA molecule, e.g. by 
binding of positively charged ligands such as PtII moieties of platinum 
compounds, results in a stabilization of the DNA duplex by decreasing 
electrostatic repulsion of negative charges of phosphate groups located at 
the complementary strands). 
 
 rb = 0.03 rb = 0.06 rb = 0.09 
cis-PtI2(NH3)2 -1.9 ± 0.1 -5.0 ± 0.1 -7.9 ± 0.3 
cisplatin -2.1 ± 0.3 -5.2 ± 0.3 -8.3 ± 0.3 
a
 Δtm is defined as the difference between the tm values of platinated and unmodified 
DNAs. 
b
 The tm values were measured in the medium containing NaClO4 (0.1 M), Tris–HCl (1 
mM, pH 7.4) and EDTA (0.1 mM). 
c
 Values shown in this table are the means ± SEM of three separate experiments. 
 
Table 2  Δtm (°C) valuesa of CT DNA modified by cis-PtI2(NH3)2 or cisplatin. b,c 
 
Thus, it is reasonable to conclude that the decreases in tm are caused by 
destabilizing conformational distortions and that these destabilizing 
factors dominate over the interstrand cross-links formed by both cis-
platinum compounds and by positive charges on platinum moieties.  
Owing to the fact that both cisPtI2 and cisplatin carry the same 2+ charge 
on platinum moiety and form approximately identical amount of 
interstrand cross-links (5 or 6%, respectively, vide supra), the values of tm 
yielded by the adducts of both complexes reflect mainly destabilizing 
effects of conformational distortions induced by the platinum-DNA 
adducts. Hence, the results of DNA melting experiments are consistent 
with the thesis that DNA adducts of cisPtI2 distort and destabilize double 
helix of DNA approximately in the same extent as DNA adducts of 
cisplatin. 
From an overall inspection of the obtained results it is evident that cisPtI2 
interacts with DNA through a mode of interaction that is very similar to 
that well documented for cisplatin. Apparently, the major difference 
consists of a somewhat slower kinetics of platinum association to DNA 
while the formed adducts are apparently the same.  
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Cellular actions of cis-Pt I2(NH3)2 
 
Afterward, the antiproliferative effects of cisPtI2 were evaluated in a 
representative panel of cancer cell lines according to the method 
described in the experimental section.  
The cancer cell panel included the following lines: PANC-1 (human 
pancreatic cancer), IGROV-1 (human ovarian cancer), A549 (human lung 
cancer), HT29 (human colon cancer), HCT116-S and HCT116-R (human 
colon cancer). These cells were exposed to increasing concentrations of 
the drugs in the range 0-200 μM; after 24 hours viable cells (determined 
by Trypan blue exclusion) were counted and the IC50 values determined. 
The measured IC50 values are reported in table 3.    
 
cell line cisplatin cis-PtI2(NH3)2 
PANC-1 2.48±0.11 0.91±0.10 
IGROV-1 25.30±0.40 7.36±0.31 
A549 5.77±0.60 3.54±0.49 
HT29 16.39±1.10 11.69±1.40 
HCT116-S 7.65±0.63 13.42±0.49 
HCT116-R 21.96±1.11 4.15±0.23 
 
Table 3  IC50 values (µM) of cisplatin and its iodo analogue in a panel of cancer cell lines. 
 
From data inspection it is evident that cisPtI2, in the four cisplatin sensitive 
cell lines, produces on the whole cytotoxic effects comparable and often 
greater than cisplatin. Extremely meaningful is the case of IGROV-1 
where the cytotoxicity of cisPtI2 is far higher than cisplatin (IC50 =7.36 μM 
versus 25.30 μM). Moreover, very remarkably, cisPtI2 is found to 
overcome completely resistance to cisplatin in the cisplatin-resistant 
HCT116-R line. These results are very relevant and unexpected if one 
considers that cisPtI2 is commonly reputed as inactive. 
The effects of cisPtI2 on the cell cycle were also analysed in HCT116-R 
cells in comparison to cisplatin; an arrest in G2/M phase is clearly 
detected in both cases as well as a decrease of the S phase (Figure 10). 
 
 
 
cis-PtI2(NH3)2: a reappraisal 
 
 
96 
 
 
A                                                             B 
 
Figure 10 Cell cycle analysis in HCT116 treated with cisplatin (A) or cisPtI2 (B). 
 
Analytical determinations were then carried out to measure intracellular Pt 
content  in HCT116-S and HCT116-R cells after exposure to equimolar 
concentrations of either cisplatin or  cisPtI2. More precisely, cells were 
exposed to a 20 µM concentration of the Pt complexes for 3 h. 
 
Results 
expressed as Pt content per cell in the various cases and as percentage 
of internalised Pt are reported in Table 4.  
 
Cell line Drug Platinum level Internalised Pt % 
HCT116-
S 
cisplatin 2.53x10-8 
µg 0,98 
HCT116-
S 
cis-
PtI2(NH3)2 
5.37x10-8 
µg 1,91 
HCT116-
R 
cisplatin 1.46x10-8 
µg 0,50 
HCT116-
R 
cis-
PtI2(NH3)2 
6.66x10-8 
µg 2,41 
 
Table 4 Platinum level (per cell) measured after exposure (3 hours) of cell lines to 20 µM 
of cisplatin and cisPtI2. 
 
From inspection of table 4 it is evident that cisPtI2 manifests a greater 
ability to enter both types of cells than cisplatin;  such difference is more 
evident in the Pt resistant cell line compared to the Pt sensitive one  (5 
folds vs 2 folds). This is possibly linked to its greater lipophilic character 
and larger  inertness.  
Furthermore, in the resistant cell line (HCT116-R), we can pinpoint the 
correlation occurring between the above IC50 values and Pt uptake in the 
sense that a greater cytotoxicity is associated to a greater Pt uptake -in 
terms of a five fold difference- proving the capability of cisPtI2 to 
overcome chemo-resistance. 
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4.1.2.3 Discussion and conclusions 
 
The substantial lack of information concerning cisPtI2 despite its striking 
similarity to cisplatin has inspired the present study; notably, some crucial 
aspects of its chemical and biological profile have been  eventually 
elucidated.   
First, we have shown that cisPtI2 manifests a solution behaviour very 
similar to cisplatin when dissolved in an aqueous medium, at 
physiological pH; indeed, as seen for cisplatin, cisPtI2 undergoes 
activation through sequential slow release of its two iodido ligands that 
are replaced by water molecules. However, the process is appreciably 
slower than in the case of cisplatin. These statements are clearly 
supported both by experimental data (see supplementary material) and 
computational analysis. The alternative hydrolysis path, where 
preferential release of NH3 ligands is observed, could  also be induced by 
changing the pH conditions. Even in this latter case the reaction route has 
been characterized by spectrophotometric analysis  and spectral 
simulations. The large differences observed between the spectral 
patterns associated to the two possible mechanisms are very consistent 
with our interpretation.  
Then, the reactions of cisPtI2 with DNA were investigated in detail in direct 
comparison to cisplatin through a robust experimental approach involving 
a variety of independent biophysical methods. Remarkably, we found that 
the pattern of DNA platination produced by cisPtI2 is highly reminiscent 
and nearly superimposable to that of cisplatin though the kinetics of the 
DNA metalation process is again appreciably slower. 
Afterward, the cellular effects induced by cisPtI2 were explored in a small 
but representative panel of solid tumor cell lines; the panel included 
PANC-1 (human pancreatic cancer), IGROV-1 (ovarian cancer), A549 
(lung cancer), HT29 (colon cancer), HCT116-S (colon cancer) and 
HCT116-R cells. Very remarkably, we observed that cisPtI2, in contrast to 
expectations and to the current opinion, is on the whole more cytotoxic 
than cisplatin in three out of four cisplatin sensitive cancer cells; on the 
other hand, cisPtI2 was found to overcome completely resistance to 
cisplatin in the cisplatin resistant HCT116-R cell line. This latter result 
implies that cisPtI2 is able to circumvent the molecular mechanisms that 
reduce sensitivity to cisplatin in the resistant line. On the other hand, it is 
unlikely that dimeric Pt species (see supplementary material) play a major 
role in the observed cytotoxicity as the latter species are detected only at 
acidic pH and in very low amounts.   
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Analytical determinations were carried out to measure Pt uptake in the 
various cases: we found that cisplatin manifested a far lower ability to 
enter cells than cisPtI2. In addition, a pronounced reduction of Pt uptake 
was detected in HCT116 resistant cells in comparison to their sensitive 
counterpart upon cisplatin treatment implying that this is most likely the 
main mechanism of resistance.  In contrast, cisPtI2 is internalised in far 
greater amounts by both cell types with resistant cells even showing a 
slightly greater Pt uptake. 
However, the correlation between the cytotoxic potency and the 
intracellular Pt content is not straightforward for both HCT116 cellular 
lines. For instance, the Pt content measured upon exposure of HCT116-S 
cells to cisPtI2 is more than two times greater compared to exposure to 
cisplatin. Yet, cisplatin produces a greater cytotoxic effect than cisPtI2 (by 
a factor 2). Pairwise, roughly comparable amounts of intracellular Pt are 
found in HCT116-R and HCT116-S cells upon exposure to cisPtI2; but 
cisPtI2 is far more  cytotoxic in the resistant cells compared to the 
sensitive ones (by a factor 3). This implies that the nature of the cells and 
the nature of the Pt complex are still important  in determining the overall 
antiproliferative effect.  
We believe that the here reported results are very meaningful and 
innovative with respect to current mechanistic knowledge on cisplatin and 
on its analogues for the following reasons: 
 
1. In contrast to expectations and to early claims of inactivity cisPtI2 
is found to produce cytotoxic effects comparable and often greater 
than those caused by cisplatin, at least in four representative 
cancer cell lines; 
2. cisPtI2 overcomes to a large extent resistance to cisplatin in a 
cancer cell line showing acquired resistance to cisplatin, being 
taken up in a far greater amount. This implies that the recognition 
processes for the two Pt complexes are distinct.  
3. However, the large differences measured in Pt uptake between 
cisPtI2 and cisplatin do not correlate with the large differences 
observed in their respective biological effects. The nature of the Pt 
complex and the type of cell still play major roles. 
4. The aquation process of cisPtI2 at physiological pH reproduces 
closely that of cisplatin- though being slower-  involving the 
progressive release of the two halide ligands; however, at slightly 
acidic pH, cisPtI2 is found to release preferentially its ammonia 
ligands at variance with cisplatin. These processes are 
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reproduced very satisfactorily through computational analysis of 
the respective spectral profiles.  t is very likely that these 
differences in reactivity between cisPtI2 and cisplatin may lead to 
different interaction modes with specific biomolecules, in particular 
with proteins, thus generating distinct pharmacological  profiles.  
5. Remarkably, cisPtI2 produces a kind of DNA damage very similar 
to cisplatin. Yet, the kinetics of Pt binding to DNA is slower and 
the final level of DNA platination appreciably lower. As the process 
of DNA platination is apparently less efficient than in the case of 
cisplatin it is unlikely that DNA is the only  or primary target for 
cisPtI2. when one considers that cisPtI2  is even more cytotoxic 
than cisplatin
. 
 
 
Altogether, the reported results delineate an extremely favourable 
biological profile for cisPtI2 and strongly warrant its further assessment in 
appropriate preclinical models. Moreover, at least in our opinion, these 
findings contain relevant implications with respect to the postulated mode 
of action of cisplatin and of its analogues. As DNA damage produced by 
cisPtI2 is, on the whole, less extensive and less important than that 
induced by cisplatin and the type of DNA lesion is basically the same, the 
view that the cytotoxic effects of cisPtI2 may arise from mechanisms other 
than DNA damage is supported. However, more studies are definitely 
needed to further substantiate this hypothesis.  
 
4.1.2.4 Experimental section 
 
Chemistry of cis-PtI2(NH3)2 
 
Synthesis of cis-PtI2(NH3)2 and UV-Vis analysis: cisPtI2 was synthesized 
according to procedure described in section 4.1.1.4. Solution behaviour of 
cisPtI2 was assessed through spectrophotometric studies performed with 
a Varian Cary 50 Bio UV-Vis spectrophotometer in buffered solutions 
without use of DMSO and in absence of NaCl. A solution of complex (10-4 
M) was prepared in 50 mM phosphate buffer (with or without presence of 
KI) at pH=7.4 or in 20 mM ammonium acetate buffer at pH=4.5 and 
absorbance monitored in the range between 200 and 800 nm of wave 
length for 72 h at 25° C. 
 
Density Functional Theory simulations: ORCA package has been used 
throughout the calculations.21 Hybrid PBE0 functional22 and Aldrich TZVP 
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gaussian basis sets with scalar relativistic (ZORA) corrections26 were 
used for both geometry optimizations and spectra simulations. Excited 
states have been computed within the TDDFT approach27 and only the 
first twenty transitions have been computed using 200 expansion vectors 
in the iterative solution of the CI equations. D3 Grimme's dispersion 
corrections25 have also been included. Solvent effects have been take 
into account within the COSMO model28,29with an  value of 80.4. Highly 
accurate integration  
grids (Grid 5 in the ORCA notation) without pruning of the inner angular 
part of the wave function and “TightSCF” convergence criteria has been 
used throughout all the calculations 
 
LogP determination: the octanol-water partition coefficients for cisplatin 
and cisPtI2 were determined by modification of reported shake-flask 
method.28 Water (50 mL, distilled after milli-Q purification) and n-octanol 
(50 mL) were shaken together for 72 h to allow saturation of both phases. 
Solution of the complexes were prepared in the water phase (3 x 10-3 M) 
and an equal volume of octanol was added. Biphasic solutions were 
mixed for ten minutes and then centrifuged for five minutes at 6000 rpm 
to allow separation. Concentration in both phases was determined by UV-
VIS. Reported logP is defined as log [complex]oct/[complex]wat. Final 
values were reported as mean of three determinations. 
 
Uptake experiment: comparison between cisplatin and cis-PtI2(NH3)2 
HCT116 cell line: the determination of platinum concentration in the 
cellular pellets as well as in the corresponding supernatant samples was 
performed in triplicate by a Varian  720-ES Inductively Coupled Plasma 
Atomic Emission Spectrometer (ICP-AES) equipped with a CETAC 
U5000 AT+ ultrasonic nebulizer, in order to increase the method 
sensitivity. Before the analysis, samples were weighted in PE vials and 
digested in a thermo-reactor at 80 °C for 24 h with 2 mL of aqua regia 
(HCl suprapure grade and HNO3 suprapure grade in 3:1 ratio) and 0.2 mL 
of H2O2 suprapure grade. After digestion, the samples were diluted to 
about 5 mL with ultrapure water (≤18 MΩ) and accurately weighed; 5.0 
mL of each sample were spiked with 1 ppm of Ge used as an internal 
standard, and analysed. Calibration standards were prepared by 
gravimetric serial dilution from a commercial standard solution of Pt at 
1000 mg L−1. The wavelength used for Pt determination was 214.424 nm 
whereas for Ge was used the line at 209.426 nm. The operating 
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conditions were optimized to obtain maximum signal intensity, and 
between each sample, a rinse solution constituted by HCl suprapure 
grade and HNO3 suprapure grade in 3:1 ratio was used in order to avoid 
any “memory effect”. 
 
Cellular studies 
 
Cell cultures: PANC-1, HCT116-S, HCT116-R, IGROV-1, A549 and HT29  
cell lines were cultured in RPMI 1640 (Euroclone; Milan, Italy) with 10% 
Fetal Bovine Serum (FBS) (Euroclone Defined; Euroclone; Milan, Italy). 
HCT116 cells were kindly provided by Dr. R. Falcioni (Regina Elena 
Cancer Insitute, Roma). We cultured at 37 °C in a humidified atmosphere 
in 5% CO2 in air. 
 
Pharmacology experiments: cells were  seeded in a 96-well flat-bottomed 
plate (Corning-Costar, Corning, NY, USA) at a cell density of 1 x 104 cells 
per well in RPMI complete medium. Drugs were used, after solubilisation 
in water, without use of DMSO, at the final concentrations indicated in the 
figures and in the legends to the figures. After 24 h, viable cells 
(determined by Trypan blue exclusion) were counted in triplicate using a 
haemocytometer. Each experimental point represents the mean of four 
samples carried out in three separate experiments.  
 
Trypan blue assay: cells viability was assessed by the Trypan blue 
exclusion assay. In brief, 10 µL of 0.4% trypan blue solution was added to 
10 µL cell suspensions in culture medium.      
The suspension was gently mixed and transferred to a haemocytometer. 
Viable and dead cells were identified and counted under a light 
microscope. Blue cells failing to exclude dyes were considered nonviable, 
and transparent cells were considered  viable. The percentage of viable 
cells was calculated on the basis of the total number of cells (viable plus 
non viable). The IC50 value (i.e., the dose that caused apoptosis of 50% of 
cells) was calculated by fitting the data points (after 24 h of incubation) 
with a sigmoidal curve using Calcusyn software.  
 
Cell cycle analysis: the effect of cisplatin and cisPtI2 on cell cycle 
distribution was assessed by flow cytometry after staining cells with 
propidium iodide (PI). Briefly, the cells (5 x 105 cells mL-1) were analyzed 
prior and after treatment with IC50s of both drugs (20.98 µM and 7.3 µM) 
for 24 h. The cells were harvested, washed with PBS and resuspended in 
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300 μL 1X Propidium Iodide staining solution and incubate at 4 °C in the 
dark for 20 minutes. DNA content of the cells was measured by BD 
FACSCanto Flow Cytometer and the population of each phase was 
determined using ModFit LT 3.0 analysis software (Verity Software 
House, Topsham, ME USA). 
 
DNA binding studies 
 
Reaction of cisPtI2 with DNA, its putative main target, was analysed in 
direct comparison with cisplatin through a robust experimental approach 
including quantification of Pt binding to DNA, DNA interstrand cross-
linking analysis, DNA adducts characterization by ethidium bromide 
fluorescence, DNA unwinding and thermal stability analyses. 
 
Quantitative evaluation of binding of cis-PtI2(NH3)2 and cisplatin to 
mammalian DNA in a cell-free medium: solutions of double-helical calf 
thymus (CT) DNA (42% G + C, mean molecular mass approximately 2 x 
107) at a concentration of 0.032 mg mL-1 (1 x 10-4 M related to the 
phosphorus content) were incubated with cisPtI2 (8 μM) or cisplatin (8 
μM) at a value of rf = 0.08 in 0.1 mM KI or KCl, respectively, at 37 °C (rf is 
defined as the molar ratio of free platinum complex to nucleotide 
phosphates at the onset of incubation with DNA). Two different stock 
solutions of cisPtI2 (0.1 mM) or cisplatin (0.1 mM) were prepared. One 
contained the PtII complex incubated for 7 days in unbuffered KI or KCl, 
respectively (0.01 M, pH 6) at 37 °C in the dark, whereas the other 
contained PtII complexes incubated for 7 days in double distilled water at 
37 °C in the dark. Fifty microliters of the PtII complex aged in KI/KCl (0.01 
M) or in water were quickly mixed with 4950 μL of DNA dissolved in 
NaClO4 (10 mM), and the reaction mixture was kept at 37 °C. In the 
experiments in which the PtII complex aged in water was used, the final 
reaction mixture was still supplemented at the onset of the reaction with 
KI or KCl so that the resulting concentration of KI or KCl in the reaction 
mixtures was always 0.1 mM. At various time intervals, an aliquot of the 
reaction mixture was withdrawn and assayed by differential pulse 
polarography (DPP) for platinum not bound to DNA.30 
 
Platination reactions:  if not stated otherwise, CT or plasmid DNAs were 
incubated with the platinum complex in 10 mM NaClO4 at 37 °C in the 
dark. After 24 h, the samples were exhaustively dialyzed against the 
medium required for subsequent biochemical or biophysical analysis. An 
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aliquot of these samples was used to determine the value of rb (rb is 
defined as the number of molecules of the platinum complex bound per 
nucleotide residue) by flameless atomic absorption spectrophotometry 
(FAAS) or by differential pulse polarography (DPP).29 
 
Unwinding of negatively supercoiled DNA: unwinding of closed circular 
supercoiled pSP73KB plasmid DNA (2455 bp) was assayed by an 
agarose gel mobility shift assay.30 The unwinding angle Φ, induced per 
platinum–DNA adduct was calculated upon the determination of the rb 
value at which the complete transformation of the supercoiled to the 
relaxed form of the plasmid was attained. Samples of pSP73KB plasmid 
were incubated with platinum compounds at 37 °C in the dark for 24 h. 
The samples were subsequently subjected to electrophoresis on 1% 
agarose gels running at 25°C with tris(hydroxymethyl) aminomethane 
(Tris)–acetate–EDTA buffer. The gels were then stained with EtBr, 
followed by photography with a transilluminator. 
 
DNA melting: the melting curves of CT DNAs were recorded by 
measuring the absorbance at 260 nm. The melting curves were recorded 
in a medium containing 10 mM or 0.1 M Na+ with 1 mM Tris–HCl/0.1 mM 
Na2H2EDTA, pH 7.4. The value of the melting temperature (tm) was 
determined as the temperature corresponding to a maximum on the first 
derivative profile of the melting curves.  
 
Interstrand DNA cross-linking in a cell-free medium: cisPtI2 or cisplatin 
were incubated for 24 h with 0.5 µg of a linear 2686-bp fragment of 
pUC19 plasmid linearized by EcoRI. The linear fragment was first 3´-end-
labeled by means of the Klenow fragment of DNA polymerase I in the 
presence of [α-32P]dATP. The platinated samples were analyzed for DNA 
interstrand crosslinks by previously published procedures.31,23  The 
number of interstrand cross-links was analyzed by electrophoresis under 
denaturing conditions on alkaline agarose gel (1%). After the 
electrophoresis had been completed, the intensities of the bands 
corresponding to single strands of DNA and interstrand cross-linked 
duplex were quantified. The frequency of interstrand cross-links was 
calculated as ICL/Pt (%) = XL/5372rb (the DNA fragment contained 5372 
nucleotide residues), where ICL/Pt (%) is the number of interstrand cross-
links per adduct multiplied by 100, and XL is the number of interstrand 
cross-links per molecule of the linearized DNA duplex, which was 
calculated assuming a Poisson distribution of the interstrand crosslinks as 
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XL = -ln A, where A is the fraction of molecules running as a band 
corresponding to the non-cross-linked DNA. 
 
Characterization of DNA adducts by EtBr fluorescence: these 
measurements were performed on a Varian Cary fluorescence 
spectrophotometer using a 1 cm quartz cell.  
Fluorescence measurements were performed at an excitation wavelength 
of 546 nm, and the emitted fluorescence was analyzed at 590 nm. The 
fluorescence intensity was measured at 25 °C in NaCl (0.4 M) to avoid 
secondary binding of EtBr to DNA.28 The concentrations were 0.01 mg 
mL−1 for DNA and 0.04 mg mL-1 for EtBr, which corresponded to the 
saturation of all intercalation sites of EtBr in DNA.32 
 
Other physical methods: Absorption spectra were measured with a 
Beckman 7400 DU spectrophotometer equipped with a thermoelectrically 
controlled cell holder. The FAAS measurements were conducted with a 
Varian AA240Z Zeeman atomic absorption spectrometer equipped with a 
GTA 120 graphite tube atomizer. The gels were visualized with a 
FUJIFILM BAS 2500 bioimaging analyzer, and the radioactivity 
associated with the bands was quantified with AIDA Image Analyzer. DPP 
measurements were performed using an EG&G PARC Electrochemical 
Analyzer, model 384B. 
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5.1 Introduction 
Re-evaluation of selected compounds that, for different reasons, have 
been overlooked in the past, may be considered a real strategy for the 
discovery of new anticancer drugs.  Along this line of reasoning, in this 
chapter we report our preliminary studies on cis-PtBr2(NH3)2, the 
dibromide analogue of cisplatin. 
5.1.1 Cisplatin and its dibromido analogue: a comparison of 
chemical and biological profiles 
5.1.1.1 Introduction 
In chapter 4 we demonstrated that the diiodido analogue of cisplatin 
manifests truly interesting biological properties and warrants a more 
extensive pharmacological evaluation.1 This encouraging result prompted 
us to prepare and evaluate even the dibromido analogue of cisplatin 
(Figure1). Accordingly, we report here on the synthesis and the chemical 
characterisation of cis-PtBr2(NH3)2 as well as on the initial assessment  of 
its biological and pharmacological  profile. 
 
 
 
Figure 1 Structure of cisplatin and its dibromido analogue. 
 
5.1.1.2 Results 
 
Solution behaviour of  cis-PtBr2(NH3)2 and its activation profile 
 
cis-PtBr2(NH3)2 shows an acceptable solubility in the reference phosphate 
buffer, at physiological pH, allowing to carry out experiments in the 
absence of DMSO or other organic solvents, thus avoiding potential 
interferences. Freshly prepared solutions of cis-PtBr2(NH3)2 manifest 
typical absorption bands in the UV-visible, with a main band at 330 nm 
and a pronounced shoulder at 300 nm (Figure 2). These bands are 
tentatively assignable to a d-d and LMCT transitions respectively in 
analogy with other cisplatin derivatives.1 After dissolution of the study 
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compound in the reference buffer, progressive spectral changes are 
observed that are assigned to the progressive release of the two bromide 
ligands. The process is similar to what observed in the case of cisplatin 
with a comparable kinetics.1  
 
Figure 2 Time course spectra of cis-PtBr2(NH3)2 10-4 M in 50 mM phosphate buffer over 
24 h, RT. 
 
Mechanistic studies: biomolecular interactions 
 
To investigate the possible interactions occurring between cis-PtBr2(NH3)2 
and its likely biomolecular targets we first performed a few ESI-MS 
experiments for samples where the study complex was incubated with the 
model protein lysozyme for a certain time period (Figure 3). First attempts 
to characterise the protein metalation process through ESI-MS detection 
were carried out by analysing samples after 24 h of incubation, but no 
clear evidence of adduct formation was obtained. However, upon 
increasing the incubation time up to 72 h, under identical solution 
conditions, a number of peaks of higher molecular weight than the native 
protein, were instead observed that are straightforwardly assigned to 
metallodrug-lysozyme adducts. From careful inspection of the spectrum, it 
is evident  that Pt coordination occurs through a mechanism that involves 
preferential detachment of halide ligands and full retention of ammonia 
ligands; assignments were validated by theoretical calculation (see 
supplementary material). This kind of protein metalation strictly resembles 
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that produced by cisplatin resulting in an adduct characterised by 
selective Pt coordination to His15 after release of the two chloride 
ligands.2 Remarkably, this behaviour being in accord with cisplatin is in 
contrast with that of cis-PtI2(NH3)2, where metalation of lysozyme occurs 
through metal fragments resulting from preferential release of the 
ammonia ligands (see chapter 4, paragraph 4.1.1).3 
 
 
 
 
Figure 3 Deconvoluted ESI-MS spectra of lysozyme treated with 3*10-4 mol L-1 of cis-
PtBr2 recorded after 72 h of incubation at 37 °C, metal : protein ratio = 3:1; ammonium 
acetate buffer 20 mmol L-1 at pH=6.8.  
  
CD experiments, interaction with CT DNA  
 
Since nuclear DNA is believed to be the primary target for the 
pharmacological effect of cisplatin,4 we have characterized the interaction 
of cis-PtBr2(NH3)2 with calf thymus DNA through CD experiments. 
The CD spectrum of CT DNA, before addition of the drugs is in keeping 
with literature (Figure 4).5 
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Figure 4 CD spectra of CT DNA without and with cis-PtBr2(NH3)2 (cis-PtBr2am2), 0.5 
equiv, measured immediately after the mixing. 
 
Addition of 0.5 equiv of cis-PtBr2(NH3)2 did not lead to any immediate 
change in the CD spectrum (Figure 4). However, after incubation at 22°C 
for 72 h, the spectrum changed  showing clear differences on the whole 
wavelength range (Figure 5). In particular, both CD bands at 280 and 250 
nm increased in intensity, the first by about 15%. 
 
-3
-2
-1
0
1
2
3
4
5
200 250 300 350
ctDNA
ctDNA + 0.5 equiv cis-PtBr2am2
ctDNA + 1 equiv cis-PtBr2am2

 
(P
) / 
M
-
1 c
m
-
1
 / nm  
 
Figure 5 CD spectra of CT DNA without and with cis-PtBr2(NH3)2 (cis-PtBr2am2) , 0.5 and 
1 equiv, after 72 h incubation. 
 
From inspection of CD we can state that spectra measured after addition 
of 0.5 or 1 equivalents of cis-PtBr2(NH3)2 were consistent and no 
significant changes in the spectral profiles were detected. Evidences that 
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cis-PtBr2(NH3)2 interacts with CT DNA very similarly to cisplatin derive 
from the comparative analysis of the CD spectra of CT DNA after 
incubation with 1 equivalent of cis-PtBr2(NH3)2 or cisplatin (Figure 6). 
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Figure 6 CD spectra of CT DNA with cis-PtBr2(NH3)2 (cis-PtBr2am2) and cisplatin, 1 
equivalent, after 72 h incubation. 
 
Cellular effects 
 
Then, we  investigated the response of a small panel of human cancer 
cell lines, to cis-PtBr2(NH3)2 treatment in terms of cell proliferation 
inhibition according to the method described in the experimental section 
(see below). The cancer cell panel included the following lines: A549 
(human lung cancer), HCT116 (human colon cancer), IGROV-1 (human 
ovarian cancer) and FLG 29.1 (human acute myeloid leukaemia). These 
cells were exposed to increasing concentrations of the drug in the 0–200 
μM range and treated for 24 hours; then IC50 values were determined 
(calculated through the Trypan blue exclusion test) (Table 1). From data 
collected  it is evident that cis-PtBr2(NH3)2, in the four cancer cell lines, 
produces, on the whole, cytotoxic effects almost superimposable to those 
of cisplatin. Quite  peculiar is just the case of the leukaemia cell line FLG 
29.1 where the cytotoxicity of cis-PtBr2(NH3)2 is significantly greater than 
cisplatin (the  IC50 is roughly  halved).  
These encouraging results led us to deepen our investigation. The effects 
of cis-PtBr2(NH3)2 on cell cycle and apoptosis were further evaluated  in 
the FLG 29.1 cell line, emerging as the most sensitive to this compound 
in comparison to cisplatin. Upon  treatment with cis-PtBr2(NH3)2 we 
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noticed  a strong reduction in the percentage of cells in the G0/G1 phase 
accompanied by an increase in G2/M more pronounced  than for cisplatin 
(see Figure 7). We next evaluated the effect of cis-PtBr2(NH3)2 in the 
induction of apoptosis by Annexin/PI test. As reported in figure 8 the 
treatment with cis-PtBr2(NH3)2 for 24 hours determined in FLG 29.1 an 
induction of apoptosis more evident than for cisplatin with a percentage of 
Annexin+/PI- cells of 51.85±4.5 versus 41.15±2.75 in the case of 
cisplatin. 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Evaluation of IC50 on a panel of tumor cell lines. A549,FLG,HCT-116 and IGROV-
1 cell lines were exposed to IC50 concentrations of Cisplatin and cis-PtBr2(NH3)2 for 24 
hours and cell viability was evaluated via Trypan Blue exclusion assay. Means and SEMs 
are relative to one experiment mounted in triplicate. 
 
 
 
 
 
A                                           B                                      C 
 
Figure 7 effect of cisplatin and cis-PtBr2(NH3)2 on cell cycle of FLG cells. Effect of 
Cisplatin and of cis-PtBr2(NH3)2  given at their IC50s on cell cycle of FLG cells after 24h of 
treatment. A=control, B=treated with cisplatin C=treated with cis-PtBr2(NH3)2. The means 
and SEMs relative to two independent experiments are reported next to each 
representative panel. 
 
IC50 Cisplatin (µM) 
mean±SEM 
IC50  cis-PtBr2(NH3)2 (µM) 
mean±SEM 
A549 8.61±0.73 10.08±0.73 
FLG 29.1 24.33±0.75 14.66±0.63 
HCT-116 20.04±0.95 28.28±3.11 
IGROV-1 24.12±0.49 25.63±0.25 
Studies on the dibromido analogue of cisplatin as potential anticancer 
agent: preliminary results 
 
 
116 
 
 
A                                           B                                      C 
 
Figure 8 effect of cisplatin and cis-PtBr2(NH3)2  on apoptosis of FLG cells. Effect of 
Cisplatin and of cis-PtBr2(NH3)2  given at their IC50s on the induction of apoptosis on FLG 
cells after 24h of treatment. The means and SEMs relative to two independent 
experiments are reported in each representative panel. A=control, B=treated with cisplatin 
C=treated with cis-PtBr2(NH3)2. 
 
5.1.1.3 Discussion and conclusions 
 
Very recently (see chapter 4) we have studied the behaviour of the 
diiodido analogue of cisplatin that turned out to show very attractive 
chemical and biological features.1 Notably the diiodido analogue 
manifests conspicuous cytotoxic effects in vitro and is able to overcome 
to a large extent resistance to cisplatin. Some peculiarities in the nature of 
the reaction of cis-PtI2(NH3)2 with model proteins were also highlighted. 
Here we have extended our investigation to the dibromido analogue in 
such a way to gain a more complete description of this issue. 
cis-PtBr2(NH3)2 could be prepared quite easily according to the classical 
synthetic procedure of Dhara with slight modifications. Its solution 
chemistry was explored in a standard physiological buffer and a 
behaviour very close to cisplatin emerged, indeed, activation cis-
PtBr2(NH3)2 occurs through bromide release.  
When reacted with the model protein lysozyme a platination pattern 
similar to cisplatin was again detected with protein coordination of 
[cisPt(NH3)2]2+ fragments. Even the process of platination of standard CT 
DNA (800 bp) is highly reminiscent of that of cisplatin and CD 
spectroscopy clearly proves the interaction. One equivalent of ligand (per 
base pair, 0.5 equiv per base) is enough to achieve full binding. The 
binding is similar for cis-PtBr2(NH3)2 and cisplatin. Using our fragmented 
ctDNA, the effects of cisplatin are different from those reported in the 
literature for non-sonicated CT DNA. 6,7  
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Cellular studies were conducted on four distinct cancer cell lines. In 
general, i.e. in 3 out of 4 cancer cell lines,  antiproliferative effects nearly 
superimposable to those caused by cisplatin were measured. More 
remarkable effects were observed only in the case of FLG cells where our 
platinum complex displayed an activity significantly greater than cisplatin 
(by about a factor 2). In the latter FLG cells cis-PtBr2(NH3)2  was also 
found to be more effective than cisplatin in producing apoptosis and in 
perturbing the cell cycle distribution. 
We believe that these differences, though quite small, might be exploited 
for further preclinical studies of this analogue and for a full assessment of 
its pharmacological profile with respect to cisplatin. Indeed, as the two 
compounds are very similar in their chemical and biological profile slight 
differences might translate into an effective therapeutic advantage and/or 
in a somewhat modified spectrum of anticancer actions for cis-
PtBr2(NH3)2  compared to cisplatin.  
 
5.1.1.4 Experimental section 
 
Chemistry of cis-PtBr2(NH3)2, synthesis and characterisation 
 
The synthesis of this Pt complex was performed through a slight 
modification of Dhara’s synthesis for cisplatin.8 A solution of 400 mg (2.4 
mmol) of KI in 3 mL of water was added to an aqueous solution (5 mL) of 
250 mg of K2[PtCl4] (0.6 mmol) which was quantitatively converted into a 
dark solution containing K2[PtI4] after five minutes of stirring at room 
temperature. Then the addition of two equivalents of ammonium 
hydroxide as a 40% solution results in the separation of cis-PtI2(NH3)2 as 
a bright yellow  compound, leaving behind a colorless solution. The solid 
was filtered off and thoroughly washed with water. (Yield 90%).   
A suspension of 200 mg of cis-PtI2(NH3)2  (0.41 mmol) in water (5mL) was 
mixed with a solution of AgNO3 (0.82 mmol) in water (1,5 mL) and stirred 
in the dark (40ºC) until a pale yellow solution was formed over the 
suspension. The AgI formed was then filter off using neutral celite over a 
solution of two equivalents of KBr in 7 mL of water. The colorless solution 
was stored until orange crystalline precipitation was observed. The bright 
orange crystals of cis-PtBr2(NH3)2 were filtered off and washed with water 
and dried in air. Yield was 25%.  Purity of the product was assessed 
through elemental analysis of C, N and H [calculated C: 0%, H: 1.45%, N: 
7.20%, experimental: C: 0,54%, H: 1.45%, N: 7.18%], 1H, 195Pt NMR and 
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IR analysis (see supplementary material). Cis geometry checked as 
describe in the literature.9 Solution behaviour of cis-PtBr2(NH3)2 was 
assessed through spectrophotometric experiments performed with a 
Varian Cary 50 Bio UV-Vis spectrophotometer in buffered solutions 
without the use of DMSO and of NaCl. A solution of the complex (10−4 M) 
was prepared in 50 mM phosphate buffer  at pH = 7.4.  The absorbance 
was monitored in the wavelength range between 200 and 800 nm for 72 h 
at 25° C.  
 
ESI-MS experiments 
 
A solution of cis-PtBr2(NH3)2 (10-4 M) was incubated with lysozyme (3:1 
metal/protein ratio) for 72 h at 37° C in 20 mmol L-1 ammonium acetate at 
pH=6.8. ESI-MS spectra were recorded after 24 and 72 h. After a 20-fold 
dilution with water, ESI MS spectra have been recorded by direct 
introduction at 5 μl min-1 flow rate in an Orbitrap high-resolution mass 
spectrometer (Thermo, San Jose, CA, USA), equipped with a 
conventional ESI source. The working conditions were the following: 
spray voltage 3.1 kV, capillary voltage 45 V, capillary temperature 220°C, 
tube lens voltage 230 V. The sheath and the auxiliary gases were set, 
respectively, at 17 (arbitrary units) and 1 (arbitrary units). For acquisition, 
Xcalibur 2.0. software (Thermo) was used and monoisotopic and average 
deconvoluted masses were obtained by using the integrated -Xtract tool. 
For spectrum acquisition, a nominal resolution (at m/z 400) of 100,000 
was used. 
 
Circular Dichroism experiments, interaction with CT DNA 
 
Sample:  CT DNA 52.0 µM (per base, P) in phosphate buffer 50 mM, 
pH=7.4; additioned with cis-PtBr2(NH3)2 2.3 mM in H2O or cisplatin 1.0 
mM in H2O, to 0.5:1 and 1:1 molar ratio (indicated per base); 1-cm quartz 
cylindrical cell, volume ca. 2.5 ml; all samples (except one, see results) 
incubated at room temperature (22°C) for 72h before measurement. The 
CT DNA has a base-pair length of ca. 800, obtained with a standardized 
procedure by sonication.10 The DNA concentration was checked by 
absorbance measurement at 260 nm (0.34 u.A., 1 cm cell). Phosphate 
buffer was used in all case to measure the blank spectrum. 
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Measurements: CD spectra measured with Jasco J-715 
spectropolarimeter with the following conditions: scan speed 50 nm/min; 
response 1 sec; data pitch 0.1 nm; bandwidth 2.0 nm; 8 accumulations.  
Cell cultures: A549 and HDF cell lines were cultured in DMEM High 
glucose (Euroclone; Milan, Italy) with 10% Fetal Bovine Serum (FBS) 
(Euroclone Defined; Euroclone; Milan, Italy). HCT-116, FLG 29.1 and 
IGROV-1 were cultured in RPMI 1640 (Euroclone; Milan, Italy) with 10% 
Fetal Bovine Serum (FBS) (Euroclone Defined; Euroclone; Milan, Italy).  
HCT116 cells were kindly provided by Dr R. Falcioni (Regina Elena 
Cancer Institute, Roma). We cultured the cell lines at 37 °C under a 
humidified atmosphere in 5% CO2 in air. 
 
Pharmacology experiments: cells were seeded in a 96-well flat-bottomed 
plate (Corning-Costar, Corning, NY, USA) at a cell density of 1 × 104 cells 
per well in either RPMI or DMEM complete medium. Drugs were used, 
after solubilisation in water, without using DMSO, in range of 
concentration of 0-200 µM. After 24 h, viable cells (determined by Trypan 
blue exclusion) were counted in triplicate using a haemocytometer. Each 
experimental point represents the mean of a single experiments carried 
out in triplicate.  
 
Trypan blue assay: cells viability was assessed by the Trypan blue 
exclusion assay. In brief, 10 µL of 0.4% trypan blue solution was added to 
10 µL cell suspensions in culture medium. The suspension was gently 
mixed and transferred to a haemocytometer. Viable and dead cells were 
identified and counted under a light microscope. Blue cells failing to 
exclude the dyes were considered nonviable, and transparent cells were 
considered viable. The percentage of viable cells was calculated on the 
basis of the total number of cells (viable plus nonviable). The IC50 value 
(i.e., the dose that caused apoptosis of 50% of cells) was calculated by 
fitting the data points (after 24 h of incubation) with a sigmoidal curve 
using Calcusyn software (Biosoft, Cambridge, UK).  
 
Cell cycle analysis: the effect of cisplatin and cisPt(NH3)2Br2 on cell cycle 
distribution was assessed by flow cytometry after staining the cells with 
propidium iodide (PI). Briefly, the cells (5 × 105 cells per mL) were 
analyzed prior to and after treatment with IC50s of both drugs for 24 h. The 
cells were harvested, washed with PBS and resuspended in 300 μL 1× 
propidium iodide staining solution and incubated at 4 °C in the dark for 20 
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minutes. DNA content of the cells was measured by BD FACSCanto 
(Becton Dickinson, Franklin Lakes, NJ, USA) Flow Cytometer and the 
population of each phase was determined using ModFit LT 3.0 analysis 
software (Verity Software House, Topsham, ME USA). 
 
Annexin/PI assay: The effects of the different drugs on our cell line panel 
was investigated through annexin V/propidium iodide (Annexin-VFLUOS 
staining kit; Roche Diagnostics, Mennheim, Germany). Cells were seeded 
at 2*105/well in 6-well plates and incubated with different drugs for 24 
hours. Cells were then harvested, washed with PBS, re-suspended in 100 
μL of binding buffer and incubated with FITC-conjugated annexin V and 
propidium iodide for 15 min. Flow cytometric analysis were performed 
with BD FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA) and 
analysed with BD FACSDiva Software 6.1.3. Each experiment was 
performed in triplicate. 
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6. PRELIMINARY ASSESSMENTS OF cis-PtI2(NH3)2 IN VIVO  
The results presented in this chapter are unpublished and have not 
been submitted to any journal to date.    
 
6.1 Introduction 
 
In vivo toxicity experiments are preclinical safety tests allowing the 
evaluation of the effects produced on the animals by the drugs, in order to 
observe the reactions produced on models that simulate the complexity of 
human organism. This allows an evaluation of correlated risk. 
Two main methods are commonly used to assess drug toxicity: acute 
toxicity test and chronic toxicity test (repeated doses).  
Acute toxicity test allows to evaluate the effects associated with a single 
administration on the animal, for which the effects are monitored for 14 
days. In case of death of the animal during the treatment, deep analysis 
are carried out to find biochemical, histological, pathological and 
morphological alterations on the animal itself. With this methodology it is 
possible to estimate the effects of the drug through determination of the 
median lethal dose (LD50). This determination implies a large group of 
animals and high mortality. This aspect led to the application of 
alternative methodologies that are more correct from an ethical point of 
view: FDP (Fixed Dose Procedure), ATC (Acute Toxic Category method) 
and UDP (Up and Down method).  
In the protocol for chronic toxicity assessment, a multiple administration 
strategy is used for a prolonged time (depending on the time are divided 
in chronic or sub-chronic). The drug is daily administered and the 
administration is repeated regularly over a period of time (at least 14 
days).  
In this type of determination mice have a weight almost uniform (± 20%). 
The group of animals should be divided in two sub-groups: 
 
1. control, i.e. mice as reference models for the standard behavior of 
the subject; 
2. treated mice that receive drug administration and undergo the 
effect of treatments  
 
During the experiment, a series of parameters (both behavioral and 
biochemical) should be monitored to assess the percentage of change 
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determined by the drug. Results are finally associated to the control of 
immunotoxicity (observed through determination of Delayed Type 
Hypersensitivity, DTH; antibody response to T-dependent antigens and 
other parameters).  
 
6.2 Experimental Protocol  
 
A solution o cis-PtI2(NH3)2  in water, with final concentration (0,9 mg/mL) 
was prepared and divided in aliquots (volume= 0,5 mL). Single-dose 
aliquots were store at -20°C until their use. At variance with cisplatin 
(administered as a solution containing NaCl in clinical protocols), cis-
PtI2(NH3)2 was solubilised in pure water without NaCl to avoid any 
interference. Also, storage at -20°C allowed to avoid hydrolysis before 
injection (see chapter 4).  
In the experiment reported in this thesis, 6 (two control) 5-week-old, 
female athymic mice (Fox1nu), have been treated with cis-PtI2(NH3)2 to 
assess chronic toxicity of this potential anticancer Pt-based drug. The 
protocol was the following: intraperitoneal injections (3.5 mg/Kg)1  2 
time/week (3 weeks treatment). Injection were made in correspondence 
of the lower right quadrant. During injection a series of data on the animal 
were collected to evaluate possible symptoms or evidence of sufferance 
induced by stress and/or drug cytotoxicity, but no evidences were found. 
Sacrifice of mice was made at the end of the protocol through preliminary 
injection of anesthetic (Avertin). The efficacy of the anesthetic was 
properly tested and verified. Afterward, dissection of mice  and collection 
of organs (i.e. liver, kidneys, spleen) and pheripheral blood (PB)  was 
carried out.       
 
6.3 Results, discussion and conclusions 
 
Obtained results highlight as in vivo chronic toxicity test carried out in a 
murine model, for the treatment with the anticancer drug cis-PtI2(NH3)2  
does not show any particular problem. 
The weight of mice was monitored during all the treatment. The first 
control was made before the first administration and the last control after 
the last administration and there was no evidence for weight loss in the 
treated mice. Remarkably, neither microscopic or macroscopic alteration 
were found in liver, kidneys and spleen. 
Furthermore, analysis of a series of serum parameters  were made to find 
eventual biochemical alterations in the treated animals (Table 1). 
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 controls treated 
AST*  69±4 IU/L 67±5 IU/L 
ALT** 30±2 IU/L 32±4 IU/L 
Creatinine*** 0.5±0.06 mg/dl 0.51±0.08 mg/dl 
*Aspartate transaminase (hepatic function) 
**Alanine transaminase (hepatic function) 
*** Renal function 
 
 Table 1 AST, ALT and creatinine value for treated and untreated mice.    
Beyond the absence of lesions in liver, kidneys and spleen, comparing 
analytical values for hepatic and renal function (i.e. AST, ALT and 
creatinine respectively) for treated and untreated mice, it emerges as 
treated animals maintain both functions, being this confirmation that 
treatment does not present any particular side effect.     
Overall, the treatment with cis-PtI2(NH3)2 has been well tolerated in 
murine models. This evidence is of great significance and strongly 
warrants for further preclinical assessments that hopefully will confirm this 
complex as very promising antineoplastic agent in those cancers resistant 
to the conventional chemotherapeutic drugs. 
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7. CONCLUSIONS  
In this work we have investigated and characterised some important 
aspect of the structure-function relationships in a panel of Pt-based 
anticancer drugs, both in widespread clinical use (i.e. cisplatin, 
carboplatin and oxaliplatin), or some promising analogues that may 
become interesting drug candidates (i.e. diiodido and dibromido 
analogues of cisplatin).   
Particular attention has been paid to the reaction of these complexes with 
the model proteins lysozyme and RNase. In fact, though it is today widely 
recognised that reaction of Pt based drugs with proteins, is of central 
importance in relation to overall pharmacological and toxicological impact 
of cisplatin and its analogues; yet, the structural information concerning 
platination of protein, and the characterization of the resulting adducts, is 
limited.  
    
In the first part of this thesis we have characterized at molecular level, 
and comparatively, the interaction of established platinum drugs cisplatin, 
carboplatin and oxaliplatin with the model proteins lysozyme and RNase, 
mainly through ESI-MS and x-ray crystallography.  
Valuable structural and functional information on these adducts was 
derived. In fact these two physicochemical techniques, in combination 
with other methods, allow, at least in selected cases, to describe in details 
and with an high accuracy the reaction of metallodrugs with protein 
targets. 
Overall, on the ground of the obtained results, a rather satisfactory and 
comprehensive description of the reactivity of cisplatin, carboplatin and 
oxaliplatin with proteins can be inferred that might be of broader validity. 
The main aspects of such reactivity are summarised below. 
All these drugs are prodrugs, i.e. they undergo an activation step before 
binding to the proteins. In particular, this step involves the detachment of 
one or more labile ligands (chloride for cisplatin, oxalate for oxaliplatin 
and CBD for carboplatin). Notably through ESI-MS analysis it is possible 
to show that the kinetic of this process may be very different for the 
mentioned drugs. This is the case of cisplatin and carboplatin for 
instance, that, despite having a very similar behavior in the binding to 
proteins, it must be stressed that cisplatin shows a rapid kinetic in the 
binding, and a greater reactivity than carboplatin in terms of amounts of 
formed derivatives. 
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From our comparative analysis it emerges that adduct formation occurs in 
a few positions, although a rather large number of potential donors, 
implying a certain selectivity in metal binding.  In addition, the two drugs 
having similar pharmacological profiles (i.e. cisplatin and carboplatin), 
exert their coordination to the protein through the same residues. 
Conversely, oxaliplatin, showing a rather different pharmacological profile, 
either in the reaction with lysozyme as well as in the reaction with Rnase, 
coordinates to the proteins in a different fashion (i.e. through a different 
bound fragment in different positions).   
From this latter consideration, a quite clear picture results, from which 
important consequences may be outlined.  
In fact we can suggest that differences in reactivity and adduct formation 
may have a more general significance and may be at the basis of the 
different pharmacological and toxicological profile of these three drugs. 
Altogether these data support previous hypotheses that metal ligands 
play a key role in the protein-metallodrug interactions, driving the drug-
biological target recognition and stabilizing the structure of the final 
adduct.  
It appears also very interesting, the coordination of cisplatin, carboplatin 
and oxaliplatin to the S-donor of amminoacidic residues, since 
coordination to sulfur atoms of glutathione or methionine is  today 
recognized to have a central role in terms of toxicity as well as in drug 
transportation.  
Mechanistic hypothesis for the binding of Pt-drugs to proteins can be 
formulated as in the case of oxaliplatin; it emerges quite clearly that 
oxaliplatin binds to the proteins through a two-step process, primarily 
involving a monodentate adduct formation, followed by ring opening 
allowing the replacement of oxalate with the carboxylate from an Asp 
residue. Noteworthy, the finding that cisplatin and oxaliplatin, bind to 
lysozyme in different sites. At least in principle, this result reflects the real 
possibility (already experimented in clinical trials) to administrate in 
combination these two drugs to overcome resistance and improve the 
efficiency of anticancer treatments.  
 
In the second part of this work we have focused our attention on two strict 
cisplatin analogues and comparatively we have considered their solution 
behaviour, their reactivity with biomolecules and the cellular effects. In 
particular the two compounds cis-PtI2(NH3)2 and cis-PtBr2(NH3)2 have 
been synthesised.  
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First of all, as reported above for established platinum anticancer drugs, 
cis-PtI2(NH3)2 has been subjected to an extensive investigation of its 
reactions with HEWL by X-ray crystallography and ESI-MS spectrometry.  
With these studies, we have provided unambiguous evidence that the 
diiodido analogue of cisplatin forms stable protein adducts containing a 
different type of protein bound metal fragment. While cisplatin typically 
affords protein platination through coordination of a [Pt(NH3)2]2+ fragment 
to selected protein side-chains, cis-PtI2(NH3)2 preferentially gives rise to a 
protein bound [PtI2NH3] fragment with full retention of the two halide 
ligands. This finding is of great interest implying that the diiodido 
analogue produces a type of biomolecular metalation remarkably distinct 
from that inferred by cisplatin. 
To assess whether the differences in the reactivity toward model proteins, 
in comparison with cisplatin, lead to some different pharmacological 
profile, we have deeply investigated cis-PtI2(NH3)2  under chemical and 
biological point of view. From our studies it emerges that in contrast to the 
expectations and to old claims of inactivity, replacement of chloride with 
iodide ligands doesn’t imply the loss of anticancer activity; producing 
cytotoxic effects comparable and often greater than those caused by 
cisplatin, at least in four representative cancer cell lines. Also, this 
complex is capable to overcome to a large extent resistance to cisplatin in 
a cancer cell line showing acquired resistance to cisplatin, being taken up 
in a far greater amount. This implies that the recognition processes for the 
two Pt complexes are distinct. 
After these promising results we started in vivo studies on murine model 
to assess the chronic toxicity of complex. From these preclinical studies it 
emerges that cis-PtI2(NH3)2, is well tolerated at the dose of 3.5 mg/Kg 
administered intraperitoneally and no evidences for lesions to spleen, 
liver and kidneys as well as alteration in hepatic and renal function were 
found. This finding, despite just a preliminary in vivo assessment, strongly 
warrants for further investigations on this complex, being now ongoing to 
determine crucial parameters such as CI (combination index) and others. 
At variance, cis-PtBr2(NH3)2 manifests a behaviour rather similar to 
cisplatin in terms of chemical features as well as in term of protein 
metalation. Cellular studies have underlined as its cytotoxic effects in vitro 
are superimposable to those of cisplatin except for leukemia FLG line 
where dibromido analogue is two times more effective than cisplatin. This 
represents an indirect confirmation that very small changes in the 
structures of these drugs may have an important impact in the final 
pharmacological effect.  
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In conclusion, the results here reported strongly support further 
investigations on iodido and dibromido derivatives drugs and  their full re-
evaluations as potential antineoplastic agents. 
Furthermore, we can state that the approach used in this study is very 
efficient since permits a detailed and accurate characterisation of the 
interaction of metal-based anticancer drugs with model proteins. The 
informations derived are of great interest in order to give a full description 
of the adducts under structural and functional point of view. Of course, 
when carrying out these experiments one should never forget that just 
very simplified systems are analysed. Real system are profoundly 
different and more complicated due to the thousands of different 
hypothetical targets. Beside it is also necessary to consider that 
obtainment of important information in a cell free system, is a task of 
great significance and a real advantage, since the intrinsic simplicity of 
the system itself, make it rapid and convenient despite a full prediction of 
the behaviour of a drug in cell systems as well as in vivo is impossible.  
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SUPPLEMENTARY MATERIAL 
3.1.3  Oxaliplatin vs Cisplatin: competition experiments  
in the binding to Lysozyme 
 
 
Figure S1 Superposition of bis-adduct (brown) and atomic resolution structure of HEWL 
(PDB code 2VB1, yellow). 
 
 
A                                                       B         
Figure S2 Details of the comparison of the HEWL structure in the bis-adduct (brown) and 
in the and atomic resolution structure (yellow, PDB code 2VB1). Major differences are 
observed at the end of helix constituted by residues 88-101 and in the loop regions 
corresponding to residues 44-51 and 69-73. These structural variations are probably 
related to the differences in the position of nitrate ions on the protein surface.  
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Figure S3 Oxaliplatin binding site in the second structure of bis-adduct (PDB code 4ZEE). 
2Fo-Fc electron density maps are contoured at 1σ (grey) level. 
 
Figure S4 Cisplatin binding site in the second structure of bis-adduct (PDB code 4ZEE). 
2Fo-Fc electron density maps are contoured at 1σ (grey) level. 
 
Figure S5 Anomalous difference map calculated from anomalous data collected for the 
second bis-adduct crystal (PDB code 4ZEE). The anomalous map is rendered in violet 
and contoured at 2.0 σ. The inspection of the map allows the identification of the positions 
of Pt and of sulphur atoms of Cys6, Met12, Cys30, Cys64, Cys76, Cys80, Cys94, Met105, 
Cys115 and Cys127. 
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Surface plasmon resonance (SPR) experiments. Real time binding assays were 
performed at 25 °C on a Biacore 3000 Surface Plasmon Resonance (SPR) instrument 
(GE Healthcare). HEWL was immobilized at 940 RU, on a CM5 Biacore sensor chip in 10 
mM sodium acetate pH 5.5, by using the EDC/NHS chemistry, with a flow rate of 5 μL x 
min-1 and an injection time of 7 min. Binding assays were carried out by injecting 90 µL of 
analyte, at 20 µL x min-1, with 20 mM sodium citrate at pH 4.4 as running-buffers. 
Experiments have been also carried out at pH 7.4 using HBS (10 mM Hepes, 150 mM 
NaCl, 3 mM EDTA, pH 7.4) as running buffer. The association phase (kon) was followed 
for 270 s, whereas the dissociation phase (koff) was followed for 300 s. The reference chip 
sensorgrams were opportunely subtracted to sample sensorgrams. Kinetic parameters 
were estimated assuming a 1:1 binding model and using version 4.1 Evaluation Software 
(GE Healthcare). A sequential injection experiment (by injecting first 30 µL of Oxaliplatin 
and then 30 µL of cisplatin at 1 mM) has been also performed using exactly the same 
experimental conditions of the single injection experiments. The inverse experiment where 
Oxaliplatin is injected after Cisplatin shows that in the short time of the experiment 
Oxaliplatin does not bind the preformed HEWL-Cisplatin adduct. 
A  
                            B  
C  
Figure S6 Overlay of sensorgrams for the interaction between Oxaliplatin (A) and 
Cisplatin (B) and HEWL. Experiments have been carried out at room temperature using 
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20 mM sodium citrate at pH 4.4 as running-buffers. In panel C, the interaction between 
HEWL and Cisplatin has been evaluated at room temperature using HBS (10 mM Hepes, 
150 mM NaCl, 3 mM EDTA, pH 7.4) as running buffer. 
 
 
 
 
Figure S7 SPR Sensorgram for the sequential injection of Cisplatin and (then) Oxaliplatin, 
both at 1 mM, to immobilized HEWL in the presence of 20 mM sodium citrate buffer at pH 
4.4. In the time of this experiment Oxaliplatin does not bind the preformed HEWL-Cisplatin 
adduct. 
 
Circular dichroism thermal denaturation experiments. Protein thermal denaturation 
experiments were performed by following the circular dichroism (CD) signal at 222 nm as 
function of temperature for HEWL, HEWL/Cisplatin, HEWL/Oxaliplatin  (protein sample 
was pre-incubated in the presence of the metallodrug for 24 h at room temperature) and 
for the bis-adduct that forms when a) HEWL is concomitantly incubated for 24 h in the 
presence of equal amount of Cisplatin and Oxaliplatin (HEWL/Cisplatin+Oxaliplatin), b) 
HEWL is first incubated for 24 h with Cisplatin and then for 24 h with Oxaliplatin 
(HEWL/Cisplatin then Oxaliplatin) and c) viceversa, i.e. HEWL is first incubated for 24 h 
with Oxaliplatin and then for 24 h with Cisplatin (HEWL/Oxaliplatin then Cisplatin). In all 
cases, final protein:metal ratio is 1:10 for each complex and protein concentration is about 
20 µM. The experiments have been carried out at pH 4.4 (10 mM sodium acetate buffer). 
A Peltier temperature controller was used to set up the temperature of the sample, with a 
slope of 20 °C/1 hour. 
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4.1.1 Peculiar features in the crystal structure of the adduct between 
lysozyme and cis-PtI2(NH3)2 
 
 
 
Figure S8 Scheme of cisplatin binding to HEWL at the right-handed site, as observed by 
Casini et al. Pt(II) has an occupancy equal to 0.3 and is bound to the nitrogens of two 
ammonia molecules in cisplatin.  
 
 
Figure S9 Anomalous electron density maps contoured at 4.0 σ in the Pt binding site, i.e. 
close to His15. The presence of three peaks of anomalous electron density close to Pt 
atom suggests the presence of two alternative mode of binding of [PtI2NH3] moiety. For 
sake of clarity just one of the two different modes of binding of cis-PtI2(NH3)2 to HEWL is 
shown. 
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4.1.2 Further insight into antineoplastic properties of cis-PtI2(NH3)2  
 
 
Figure S10 UV-Vis spectrum of complex cis-Pt(NH3)2I2 10-4 M with 10-3 M KI in 50 mM 
phosphate buffer (pH=7.4) followed for 72 h. 
 
 
Figure S11 Time dependent UV-Vis spectrum of cisplatin 10-4 M buffer phosphate 50 mM 
pH=7.4 recorded for 72 h at RT. 
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Figure S12 Time dependent UV-Vis spectrum of cisplatin 10-4 M buffer phosphate 50 mM 
pH=7.4 recorded for 72 h at RT. isosbestic points of the two complexes (285 nm for 
cisplatin and 284 cisPtI2), drift during the analysis, this is the evidence that allows us to 
hypothesize a biphasic reaction with two very close rate constants.1 
 
 
Figure S13 Detail on isosbestic point for time dependent UV-Vis spectrum of cisPtI2 10-4M 
buffer phosphate 50 mM pH=7.4 recorded for 72 h at RT. 
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Final products analysis. we have considered as final UV-Vis spectrum the spectral 
profile recorded after 72 h, since after this time there are no evidences for changes in 
absorbance within the investigated range (200-800 nm). For both complexes, there are 
evidences of existence of the same species characterised by two absorption bands at 285 
and 350 nm, as result from deconvoluted spectral profiles. The relative differences 
existing between DFT calculation and experimental spectral profiles may be assignable to 
various equilibria determined by pH value. Acid dissociation constants for coordinated 
water molecules in products cis-[PtCl(H2O)(NH3)]+, cis-[Pt(H2O)2(NH3)2]2+  and cis-
[Pt(H2O)(OH)(NH3)2]+ are 6.41; 5.37; 7.21 and using buffered solution at pH=7.4 it is 
reasonable to hypothesise a series of equilibria that produce different species (i.e. 
hydroxo species) in different ratio.2 In a similar manner same process are likely involved  
in the hydrolysis of cisPtI2.  
 
Figure S14 Detail on deconvolution of final product spectral profile for time dependent 
UV-Vis spectrum of cisplatin 10-4M buffer phosphate 50 mM pH=7.4 recorded for 72 h at 
RT. 
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Figure S15 Detail on deconvolution of final product spectral profile for time dependent 
UV-Vis spectrum of cisPtI2 10-4M buffer phosphate 50 mM pH=7.4 recorded for 72 h at 
RT. 
Pseudo first-order rate constant calculation. According to Miller et al.,1 it is possible to 
analyse these experimental time dependent spectral profiles treating the hydrolysis 
process as a pseudo-first order reaction. Calculations were done plotting the variation of 
absorbance as function of time for both cisPtI2 and cisplatin respectively monitoring the 
maxima at 350 and 305 nm. 
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Figure S16 Experimental kinetic traces and calculated theoretical curve for the 
hydrolysis of cisPtI2. kobs were calculated fitting with a single exponential function. 
 
  k
obs (s
-1) [1/t] t1/2 (min) 
[t*ln(2)] 
cisplatin 2,96*10
-5
 
395±66 
cisPtI2 1,77*10
-5
 
639±11 
 
Table S1 Kobs and t1/2 values determined fitting with a single exponential function. 
 
ESI-MS experiment. cis-Pt(NH3)2I2 was solubilized in ammonium acetate  buffer pH= 4.5, 
and ESI-MS spectra were recorded by direct introduction at 5 μl/min flow rate in an 
Orbitrap high-resolution mass spectrometer (Thermo, San Jose, CA, USA), equipped with 
a conventional ESI source. The working conditions were the following: spray voltage 3.1 
kV, capillary voltage 45 V, capillary temperature 220°C, tube lens voltage 230 V. The 
sheath and the auxiliary gases were set, respectively, at 17 (arbitrary units) and 1 
(arbitrary units). For acquisition, Xcalibur 2.0. software (Thermo) was used and 
monoisotopic and average deconvoluted masses were obtained by using the integrated 
Xtract tool. For spectrum acquisition a nominal resolution (at m/z 400) of 100,000 was 
used. 
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Figure S17 ESI-MS spectrum of complex cis-Pt(NH3)2I2 10-4 M in 20 mM ammonium 
acetate buffer (pH=4.5). 
DNA interstrand cross-linking in the linear pUC19 DNA (linearized with EcoRI 
restriction enzyme). In order to  quantitate the interstrand cross-linking efficiency of cis-
PtI2(NH3)2 the above reported linearized plasmid DNA was 3´-end-labeled and modified by 
the cis-PtI2(NH3) or cisplatin at various rb values. The samples were analyzed for the 
interstrand cross-links (CLs) by agarose gel electrophoresis under denaturing conditions.3 
Upon electrophoresis, 3′-end labeled strands of the linear fragment containing no 
interstrand CLs migrate as a 2686-base single strand, whereas the interstrand cross-
linked strands migrate more slowly as a higher molecular mass species (Figure S18). The 
intensity of the more slowly migrating band increased with the growing level of the 
modification. The radioactivity associated with the individual bands in each lane was 
measured to obtain estimates of the fraction of noncross-linked or cross-linked DNA under 
each condition. The frequency of interstrand CLs was calculated using the Poisson 
distribution from the fraction of interstrand cross-linked DNA in combination with the rb 
values and the fragment size.4  
 
 
Figure S18 Formation of interstrand cross-links. Interstrand cross-linking by cis-PtI2(NH3)2 
and cisplatin in the linear pUC19 plasmid DNA. Autoradiogram of denaturing 1% agarose 
gels of linearized DNA which was 3′-end labeled. The interstrand cross-linked DNA 
appears as the top bands migrating on the gel more slowly than the single-stranded DNA 
(contained in the bottom bands). Lanes: 1, control, unplatinated DNA; 2-5, DNA modified 
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by cisplatin; 6-9, DNA modified by cis-PtI2(NH3)2. rb values: 0.0003 (lanes 2 and 6); 0.0005 
(lanes 3 and 7); 0.0007(lanes 4 and 8); 0.001 (lanes 5 and 9). 
DNA unwinding. Native agarose electrophoresis is used to determine the unwinding 
induced in negatively supercoiled plasmid DNA by monitoring the degree of supercoiling.5 
A compound that unwinds the DNA duplex reduces the number of supercoils in closed 
circular DNA. This decrease causes a decrease in the rate of migration through agarose 
gel, which makes it possible to observe and quantify the mean value of unwinding per 
adduct. Figure S19 shows electrophoresis gels from experiments in which different 
amount of cis-[PtI2(NH3)2] was bound to a mixture of relaxed and negatively supercoiled 
pSP73KB. Interestingly, both complexes increased the mobility of the relaxed form 
similarly as does cisplatin, whose bifunctional binding to DNA shortens and condenses the 
DNA helix.6,7 The mean unwinding angle is given by Φ = -18σ/rb(c), where σ is the 
superhelical density and rb(c) is the value of rb at which the supercoiled and nicked forms 
comigrate.5 Under the present experimental conditions, the value for σ of plasmid DNA 
used in these experiments was calculated to be -0.072 on the basis of the data of cisplatin 
for which the rb(c) was determined in this study and Φ = 13° was assumed.5 
 
Figure S19 Unwinding of negatively supercoiled pSP73KB plasmid DNA by platinum 
complexes. The top bands (oc) correspond to nicked plasmid and the bottom bands (sc) 
correspond to the closed, negatively supercoiled plasmid. A) Cisplatin. Lanes: 1, control, 
nonmodified DNA, 2–10 rb = 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09,0.11, respectively. B) 
cis-PtI2(NH3)2. Lanes: 1, control, nonmodified DNA, 2–8 rb = 0.05, 0.07, 0.09, 0.1, 0.12, 
0.14, 0.16, respectively. 
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5.1.1 Cisplatin and its dibromido analogue: a comparison of 
chemical and biological profiles 
A  
A  
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B  
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C  
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D  
 
D  
 
Figure S20 Comparison between experimental and theoretical peaks for the main 
adducts.    
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Figure S21 IR of the compound cis-PtBr2(NH3)2 from 600 to 200 cm-1. 
 
Figure S22 195Pt NMR of the compound cis-PtBr2(NH3)2 in DMSO. 
. 
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